

FIG. 4. Morphology of colonies produced by BFU-E and CFU-GM. Photographs of colonies cultured in nitrocellulose medium are shown at an $\times 75$ magnification by a microscope. The left column shows BFU-E, and the right column shows CFU-GM. The upper section shows colonies from uninfected monkeys, while the lower section shows colonies from monkeys infected with SHIV C2/1.

or by the antibody-dependent cell-mediated cytolytic mechanism, (ii) damage of the thymus or the lymphoid tissue, (iii) abnormal turnover of infected cells in the peripheral blood (i.e., apoptosis), and (iv) suppression of hematopoietic progenitor cells (23).

In this report, we showed that the remarkable decrease in the colony formation occurred during the early stage of infection with SHIV C2/1 (days 1 through 3 postinoculation). These results suggest that the hematopoietic progenitor cells are damaged or defective during such an early phase of infection. Furthermore, the CD4/CD8 ratio in monkey 4345 decreased within several hours, compared with controls (Fig. 1). We used ketamine for viral or saline inoculation, blood sampling, and autopsy. Ketamine has safely been used for bone marrow aspiration in humans and monkeys (21, 22, 26, 34, 35). It would be unlikely, therefore, that such bone marrow suppression occurred as a result of the anesthetic agent. However, our anesthetic procedure probably induces the release of corticosteroids in animals by the stress of capture and injection, which may have a negative impact on the colony formation. Our observation of the ability of bone marrow cultures from sham-inoculated controls to produce BFU-E and CFU-GM at days 1 and 3 proved otherwise.

After day 56, the ability of the bone marrow to form colonies recovered despite the preceding viremia and the continuing reduction of CD4/CD8 ratio. Furthermore, the colony formation was maintained at a level comparable to that of the control monkeys toward the terminal stage. Many reports have noted that CFU-GM growth continuously declines in SHIV infection, and such a decline appears to correlate with disease activity (20). However, CD4/CD8 ratio may not reflect the ongoing status of the bone marrow. A reason for the continuous reduction of CD4/CD8 ratio could be that infected T lymphocytes were destroyed in the peripheral blood more than they were produced in the bone marrow. This could be due to enhanced apoptosis or ongoing destruction of T cells by the antibody-dependent cell-mediated cytolytic mechanism in SHIV infection (24).

In contrast to previous reports, our results clearly showed that the decreasing CFU-GM growth recovered in the advanced stage, suggesting that the damage to colony formation during the early stage is reversible. We showed by PCR in this

report that the direct infection of bone marrow progenitor cells with SHIV C2/1 was minimal (3, 5, 13, 18). It is possible, however, that the number of colonies was too low for detection of SHIV C2/1 virus or that SHIV C2/1 virus-infected cells were already removed by the host immune system before the assays (6, 8, 13).

It has been reported that the cellularity of the bone marrow from patients with HIV does not always correlate with the peripheral blood abnormalities (4). The commonly seen pancytopenia is often associated with hypercellular bone marrow where the increased number of lymphocytes, plasma cells, or histiocytes is seen. The latter finding suggests either dysmyelopoiesis or increased peripheral destruction of blood cells. Yoshino et al. have recently reported that atypical lymphocytes and monocytes were observed in the peripheral blood following intense viremia on the 10th to 14th days of SHIV infection (33). They further found erythroid multinucleation and atypical mononuclear cells in the hypercellular bone marrow, suggesting direct viral infection of hematopoietic progenitor cells (33).

As mentioned above, the colony formation in the bone marrow of the infected monkeys recovered spontaneously following viremia, suggesting that the reduced colony formation capability was reversible. It has been reported that inhibition of SIV replication in bone marrow macrophages resulted in increased colony growth of progenitor cells (32), and administration of recombinant human GM colony-stimulating factor could reverse leukocytopenia (11). Our data thus support the concept that, in the early phase, production of inhibitory factors or a lack or an inhibition of stimulatory cytokine production from lymphoid cells may be responsible for some of the bone marrow kinetic defects previously described in HIV (14, 28, 29). It is necessary to determine and verify what factor is participating in the regulation and recovery of the bone marrow CFU-GM growth.

The highly pathogenic SHIV C2/1 virus is an interesting tool to study the effect of HIV and SHIV infection on hematopoietic progenitor cells (15, 17, 25). Such studies will help us understand the pathophysiology of AIDS and contribute to the development of vaccines in humans (12).




FIG. 5. Detection of SIVmac239 *gag* sequence in bone marrow colonies by PCR. Lanes: 1, a DNA ladder marker, *HincII*; 2, a negative control; 3, a positive control, a DNA sample from cell line M8166; 4, CFU-GM from monkey 4345 at the early stage; 5, CFU-GM from monkey 430 at the advanced stage; 6, CFU-GM from monkey 039 at the advanced stage (this monkey died of AIDS on day 238).

ACKNOWLEDGMENTS

This work was supported by the AIDS Research Center, NIID, Japan.

We express our appreciation to T. Nakasone and Y. Izumi, NIID, and M. Teramura, Tokyo Women's Medical University, for their quantitative analysis of plasma viral load and instruction in the stem cell culture system. We also thank K. Suzuki, Nihon University School of Medicine, Department of Public Health, for his statistical analysis and R. Suenaga for critical reading of the manuscript.

REFERENCES

- Bagnara, G. P., G. Zauli, M. Giovannini, M.C. Re, and G. Furlini. 1990. Early loss of circulating haematopoietic progenitors in HIV-1-infected subjects. *Exp. Hematol.* 18:426-430.
- Candido, A., P. Rossi, G. Menichella, L. Pierelli, E. Pizzigallo, G. Camilli, C. Rumi, and G. Mango. 1990. Indicative morphological myelodysplastic alterations of bone marrow in overt AIDS. *Haematologica* 75:327-333.
- Chelucci, C., H. J. Hassan, C. Locardi, D. Bulgarini, E. Pelosi, G. Mariani, U. Testa, M. Federico, M. Valtieri, and C. Peschle. 1995. In vitro human immunodeficiency virus-1 infection of purified haematopoietic progenitors in single-cell culture. *Blood* 85:1181-1187.
- Costello, C. 1998. Haematological abnormalities in human immunodeficiency virus (HIV) disease. *J. Clin. Pathol.* 41:711-715.
- Davis, R. D., D. H. Schwartz, J. C. Marx, C. E. Johnson, J. M. Berry, J. Lyding, T. C. Mergan, and A. Zander. 1991. Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo. *J. Virol.* 65:1985-1990.
- DeLuca, A., L. Teofili, A. Antinori, M. S. Iovino, P. Mencarini, E. Visconti, E. Tamburrini, G. Leone, and L. Ortona. 1993. Haematopoietic CD34⁺ progenitor cells are not infected by HIV-1 in vivo but show impaired clonogenesis. *Br. J. Haematol.* 85:20-24.
- Donahue, R. E., M. M. Johnson, L. I. Zon, S. C. Clark, and J. E. Groopman. 1987. Suppression of in vitro haematopoiesis following human immunodeficiency virus infection. *Nature* 326:200-203.
- Fulks, T. M., S. W. Kessler, J. M. Orenstein, J. S. Justement, E. S. Jaffe, and A. S. Fauci. 1988. Infection and replication of HIV-1 purified progenitor cells of normal human bone marrow. *Science* 242:919-922.
- Geissler, R. G., O. G. Ottmann, K. Kleiner, U. Mentzel, A. Bickelhaupt, D. Hoelzer, and A. Ganser. 1993. Decreased haematopoietic colony growth in long-term bone marrow cultures of HIV-positive patients. *Res. Virol.* 144:69-73.
- Godwin, J. H. 1999. HIV/AIDS case histories: diagnostic problems. *AIDS Patient Care STDs* 13:303-305.
- Groopman, J. E., R. T. Mitsuyasu, M. J. DeLeo, D. H. Oette, and D. W. Golde. 1987. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. *N. Engl. J. Med.* 317:593-598.
- Hayami, M., T. Igarashi, T. Kuwata, M. Ui, T. Haga, Y. Ami, K. Shinohara, and M. Honda. 1999. Gene-mutated HIV-1/SIV chimeric viruses as AIDS live attenuated vaccines for potential human use. *Leukemia* 13:42-47.
- Hillyer, C. D., D. A. Lackey III, F. Villinger, E. F. Winton, H. M. McClure, and A. A. Ansari. 1993. CD34⁺ and CFU-GM progenitors are significantly decreased in SIVsmm9 infected rhesus macaques with minimal evidence of direct viral infection by polymerase chain reaction. *Am. J. Hematol.* 43:274-278.
- Leiderman, I. Z., M. L. Greenberg, B. R. Adelsberg, and F. P. Siegal. 1987. A glycoprotein inhibitor of in vitro granulopoiesis associated with AIDS. *Blood* 70:1267-1272.
- Lu, Y., P. Brosio, M. Lafaille, J. Li, R. G. Collman, J. Sodroski, and C. J. Miller. 1996. Vaginal transmission of chimeric simian/human immunodeficiency viruses in rhesus macaques. *J. Virol.* 70:3045-3050.
- Murandin, A., A. Katz, E. Oksenhendler, M. Tulliez, F. Picard, W. Vainchenker, and F. Louache. 1996. Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection. *Blood* 88:4568-4578.
- Miller, C. J., M. Marthas, J. Greenier, D. Lu, P. J. Dailey, and Y. Lu. 1998. In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques. *J. Virol.* 72:3248-3258.
- Molina, J. M., D. T. Scadden, M. Sakaguchi, B. Fuller, A. Woon, and J. E. Groopman. 1990. Lack of evidence for infection of or effect on growth of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus. *Blood* 76:2476-2482.
- Mori, K., Y. Yasutomi, S. Olgimoto, T. Nakasone, S. Takamura, T. Shioda, and Y. Nagai. 2001. Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain. *J. Virol.* 75:4023-4028.
- Moses, A., J. Nelson, and G. C. Bagby, Jr. 1998. The influence of human immunodeficiency virus-1 on hematopoiesis. *Blood* 91:1479-1495.
- Parker, R. L., R. A. Mahan, D. Giugliano, and M. M. Parker. 1997. Efficacy and safety of intravenous midazolam and ketamine as sedation for therapeutic and diagnostic procedures in children. *Pediatrics* 100:732-733.
- Perkocha, L. A., and G. M. Rodgers. 1988. Hematologic aspects of human immunodeficiency virus infection: laboratory and clinical considerations. *Am. J. Hematol.* 29:94-105.
- Reinberger, S., M. Spring, T. Nislein, C. Stahl-Hennig, G. Hunsmann, and U. Dittmer. 1999. Kinetics of lymphocyte apoptosis in macaques infected with different simian immunodeficiency viruses or simian/human immunodeficiency hybrid viruses. *Clin. Immunol.* 90:141-146.
- Sasaki, Y., Y. Ami, T. Nakasone, K. Shinohara, E. Takahashi, S. Ando, K. Someya, Y. Sasaki, and M. Honda. 2000. Induction of CD95 ligand expression on T lymphocytes and B lymphocytes and its contribution to apoptosis of CD95-up-regulated CD4 T lymphocytes in macaques by infection with a pathogenic simian/human immunodeficiency virus. *Clin. Exp. Immunol.* 122:381-389.
- Shinohara, K., K. Sakai, S. Ando, Y. Ami, N. Yoshino, E. Takahashi, K. Someya, Y. Sasaki, T. Nakasone, Y. Sasaki, M. Kaizu, Y. Lu, and M. Honda. 1999. A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. *J. Gen. Virol.* 80:1231-1240.
- Slonim, A. D., and F. P. Ognibene. 1998. Sedation for pediatric procedures, using ketamine and midazolam, in a primarily adult intensive care unit: a retrospective evaluation. *Crit. Care Med.* 26:1900-1904.
- Steinberg, H. N., C. S. Crumpacker, and P. A. Chatis. 1991. In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus. *J. Virol.* 65:1765-1769.
- Stella, C. C., A. Ganser, and D. Hoelzer. 1987. Defective in vitro growth of the haematopoietic progenitor cells in the acquired immunodeficiency syndrome. *J. Clin. Invest.* 80:286-293.
- Stutte, H. J., H. Müller, S. Falk, and H. L. Schmidts. 1990. Pathophysiological mechanisms of HIV-induced defects in haematopoiesis: pathology of the bone marrow. *Res. Virol.* 141:195-200.
- Thiebot, H., F. Louache, B. Vastin, T. D. Revel, O. Neildez, J. Larghero, W. Vainchenker, D. Dormont, and R. L. Grand. 2001. Early persistent bone marrow hematopoiesis defect in simian/human immunodeficiency virus-infected macaques despite efficient reduction of viremia by highly active antiretroviral therapy during primary infection. *J. Virol.* 75:11594-11602.
- Thiele, J., T. K. Zirbes, P. Wiemers, J. Lorenzen, H. M. Kvasnicka, and R. Fischer. 1997. Incidence of apoptosis in HIV-myelopathy, myelodysplastic syndromes and non-specific inflammatory lesions of the bone marrow. *Histopathology* 30:307-311.
- Watanabe, M., D. J. Ringler, M. Nakamura, P. A. Delong, and N. L. Letvin. 1990. Simian immunodeficiency virus inhibits bone marrow hematopoietic progenitor cell growth. *J. Virol.* 64:656-663.
- Yoshino, N., T. Ryu, Y. Ami, K. Shinohara, M. Kaizu, Y. Izumi, T. Nakasone, and M. Honda. 2000. Pathogenic SHIV induce dysplastic hematopoiesis which may be resulted from the effect on hematopoietic progenitor cells and may affect progression to disease-state in monkeys. p. 302. *In Abstract book, vol. 1. The 13th International AIDS Conference, Durban, South Africa.*
- Young, S. S., A. M. Schilling, S. Skeans, and G. Ritacco. 1999. Short duration anaesthesia with medetomidine and ketamine in cynomolgus monkeys. *Lab. Anim.* 33:162-168.
- Zafer, T., S. Javaid, M. Saleem, Z. A. Malik, and M. F. Khattak. 1997. Ketamine for bone marrow aspiration and trephine biopsy in children. *J. Pak. Med. Assoc.* 47:304-305.
- Zon, L. I., and J. E. Groopman. 1988. Hematologic manifestations of the human immune deficiency virus (HIV). *Semin. Hematol.* 25:208-218.

A Novel Adjuvant for Mucosal Immunity to HIV-1 gp120 in Nonhuman Primates¹

Naoto Yoshino,^{2*} Fabien X.-S. Lü,[†] Kohtaro Fujihashi,^{3*} Yukari Hagiwara,^{*} Kosuke Kataoka,^{*} Ding Lu,[†] Linda Hirst,[†] Mitsuo Honda,[‡] Frederik W. van Ginkel,^{*} Yoshifumi Takeda,[§] Christopher J. Miller,[†] Hiroshi Kiyono,^{*||} and Jerry R. McGhee^{*}

The development of a safe and effective mucosal adjuvant is a crucial step toward a mucosal HIV/AIDS vaccine. This study seeks to determine the promise of a nontoxic mutant of cholera toxin (mCT; E112K) as a mucosal adjuvant in nonhuman primates. HIV-1 gp120 was nasally administered together with mCT E112K or native CT (nCT) as adjuvant on five to six occasions over a 6- to 8-wk period to groups of four rhesus macaques and alone to two monkeys that acted as controls. Macaques given nasal gp120 with either mCT E112K or nCT showed elevated gp120-specific IgG and IgA Ab responses with virus-neutralizing activity in both their plasma and mucosal external secretions, as well as higher numbers of gp120-specific IgA Ab-forming cells in their mucosal and peripheral lymphoid tissues and of IL-4-producing Th2-type CD4-positive (CD4⁺) T cells than did controls. Even though significant mucosal adjuvant activity was seen with both mCT E112K and nCT, neuronal damage was observed only in the nCT-treated, but not in the control or mCT E112K-treated groups. These results clearly show that mCT E112K is an effective and safe mucosal adjuvant for the development of a nasal HIV/AIDS vaccine. *The Journal of Immunology*, 2004, 173: 6850–6857.

It is well known that HIV-1 infections occur through contact with contaminated blood or during unprotected vaginal or anal intercourse. Indeed, it is estimated that 70–85% of HIV-1 infections are transmitted sexually (1–3). Given that fact, immune responses at mucosal surfaces in which the virus crosses the epithelium of the genital or rectal tracts are an essential component of vaccine-induced protection. The evidence for an association between mucosal immune responses and protection in humans has stemmed from studies on the immune system of women who remained seronegative despite a high rate of exposure to HIV-1. High levels of secretory IgA were detected in the genital secretions of the protected women (4–7). Because the mucosa of the small and large intestine are the largest source of lymphocytes and APCs in the host (8, 9), they act as a potential reservoir for HIV-1-infected cells in viral pathogenesis (10). Studies to develop a HIV/AIDS mucosal vaccine have been conducted in nonhuman primate (NHP)⁴ models by using recombinant

SIV proteins or peptides (11–17), live-attenuated SIVs (18–23), SIV-encoded virus or bacterial vectors (24–29), DNA vaccines (30–33), and a prime/boost regimen (34–36). Collectively, these studies point to the importance of a mucosal HIV/AIDS vaccine for the prevention of HIV-1 infection.

Recent studies have shown that nasal immunization is the most effective approach for the induction of both mucosal and systemic immune responses (37). For example, nasal immunization with protein/peptide vaccines together with mucosal adjuvant more effectively induces mucosal immunity in the female reproductive tract than does oral immunization (38). Like its gut-associated lymphoreticular tissue counterpart in the gastrointestinal tract, the nasopharyngeal-associated lymphoreticular tissue-based immune system is key to the induction of Ag-specific mucosal and systemic immune responses (39–41). In this regard, we have shown that nasal immunization of rhesus macaques with SIV p55^{gag} together with native cholera toxin (nCT) as mucosal adjuvant induced p55^{gag}-specific IgA and IgG Ab responses in vaginal secretions (16).

Although a potent mucosal adjuvant, nCT is not practical for use in humans because of its toxicity. Nasal application of CT B subunit (CT-B) or nCT resulted in its accumulation in the olfactory bulbs of the CNS through GM1 binding and in its subsequent retrograde axonal transport into the olfactory neurons (39). Furthermore, nCT is known to induce high levels of total and Ag-specific IgE Ab responses due to the nature of IL-4-dependent adjuvant activity (40–43). To overcome these potent pathological problems of nCT, we have developed and characterized two nontoxic mutants of cholera toxin (mCT; E112K and S61F) that retain adjuvant properties despite lacking the ADP-ribosyltransferase enzyme activity associated with toxicity (42, 43). Studies by our own group and by others have shown that mutant CT E112K is one of the most effective, safe, and stable adjuvants among the toxin-based mutants that have been tested (41–43).

^{*}Departments of Oral Biology and Microbiology, Immunobiology Vaccine Center, University of Alabama, Birmingham, AL 35294; [†]California Regional Primate Research Center, Department of Pathology, School of Medicine, University of California, Davis, CA 95616; [‡]AIDS Research Center, National Institute of Infectious Diseases, [§]Jissen Women's College, and ^{||}Division of Mucosal Immunology, Department of Microbiology and Immunology, Institute for Medical Sciences, University of Tokyo, Tokyo, Japan

Received for publication May 17, 2004. Accepted for publication September 9, 2004.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This study was supported by U.S. Public Health Service Grants RR13149, AI 35932, AI 18958, DK 44240, AI 43197, DE 12242, and P30 DK 54781, and grants from the Ministry of Health and Labor, and the Ministry of Education, Science, Culture, and Sports, Core Research for Engineering, Science, and Technology-Japan Science and Technology Agency, Japan.

² Current address: Department of Microbiology, Iwate Medical University School of Medicine, 19-1, Uchimaru, Morioka 020-8505, Japan.

³ Address correspondence and reprint requests to Dr. Kohtaro Fujihashi, Department of Oral Biology, School of Dentistry, Immunobiology Vaccine Center, University of Alabama at Birmingham, 761 Beville Biomedical Research Building, 845 19th Street South, Birmingham, AL 35294-2170. E-mail address: kohtarof@uab.edu

⁴ Abbreviations used in this paper: NHP, nonhuman primate; AFC, Ab-forming cell; LP, lamina propria; mCT, nontoxic mutant of cholera toxin; MLN, mesenteric lymph

node; nCT, native cholera toxin; NGF, nerve growth factor; NP, nasal passage; SMG, submandibular gland.

Because HIV-1 is most often transmitted via mucosal surfaces, a mucosal vaccine capable of inducing protective Abs and/or CTLs in mucosal tissues and external secretions would act as a first line of defense at the site of initial invasion. We take the first step toward the ultimate goal of developing a safe and effective mucosal adjuvant for a mucosal HIV/AIDS vaccine in humans by assessing in this study the efficacy and safety of mCT E112K as a mucosal adjuvant in nonhuman primates.

Materials and Methods

HIV-1 immunogen and adjuvant used

HIV-1_{LAI} Env gp120 was kindly provided by Quality Biologicals (Gaithersburg, MD) through Contract N01-AI 65278 of the Vaccine Research and Development Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. *Escherichia coli* strains containing the plasmids for the mCT E112K were grown in Luria-Bertani medium (10 mg/ml NaCl, 5 mg/ml yeast extract, 10 mg/ml tryptone) with 100 µg/ml ampicillin (42, 43). The mCT E112K was purified using a D-galactose-immobilized column (Pierce, Rockford, IL) from a cell suspension prepared by sonication of the recombinant *E. coli*, as described previously (42, 43). The purity of mCT E112K was assessed by SDS-PAGE, and no contaminating proteins were noted. The nCT was purchased from List Biological Laboratories (Campbell, CA).

Rhesus macaques

Five mature female and seven male rhesus macaques (*Macaca mulatta*), bred in captivity and reproductively cycling, were obtained from the California Regional Primate Research Center (Davis, CA). They were confirmed negative for Abs to HIV-2, SIV, type D retrovirus, and simian T cell lymphotropic virus-1 (STLV-1), and were maintained in conditions that fully complied with the standards of the American Association of Accreditation of Laboratory Animal Care at the California Regional Primate Research Center.

Immunization methods and schedule used

Rhesus macaques were divided into four groups and nasally immunized with vaccine containing: 1) 100 µg of gp120 alone, 2) 100 µg of gp120 plus 10 µg of nCT, 3) 100 µg of gp120 plus 25 µg of mCT E112K, or 4) 100 µg of gp120 plus 100 µg of mCT E112K. Macaques were anesthetized with ketamine and placed in dorsal recumbency with head tilted back so that the nares were pointed upward (16). Vaccine solution (0.5 ml) was instilled dropwise into each nostril without inserting the syringe into the nasal cavity. Macaques were kept in that position for 10 min and then placed in lateral recumbency until they recovered from anesthesia, as described previously (16). Nasal immunization was conducted on days 0, 7, 14, 28, 42, and 56.

Collection of peripheral blood, tissues, and external secretion samples and lymphocyte isolation

Tissues and peripheral blood were harvested using sterile techniques, and appropriate biohazard precautions were observed. The PBMCs were isolated from heparinized peripheral blood using Lymphocyte-Mammal (Cedarlane Laboratories, Hornby, Canada) (44). Plasma, vaginal washes consisting of a mixture of cervical and vaginal secretions, rectal washes, nasal washes, and saliva were collected, as previously described (16). These four external secretions along with the plasma were stored at -80°C until used for the analysis of gp120-specific Ab responses. For isolation of lymphocytes from different mucosal tissues, a modified enzymatic dissociation procedure was used (15, 16). Nasal passages (NP) and submandibular glands (SMG) were dissociated using collagenase type IV (0.5 mg/ml; Sigma-Aldrich, St. Louis, MO) in RPMI 1640 (Mediatech, Washington, DC) for 30 min at 37°C. After removal of Peyer's patches, the small intestine was treated first with PBS containing 1 mM DTT and then with 1 mM EDTA, while lamina propria (LP) mononuclear cells were isolated using the same method as for the NPs. The lymphocytes from tissues were purified using a discontinuous 40 and 75% Percoll gradient (Amersham Biosciences, Piscataway, NJ), as described previously (15, 16).

Monoclonal Abs

The mAbs used for cell surface staining in flow cytometric analysis were as follows: FITC-, PE-, or PerCP-conjugated mAb to human CD3 (SP34; BD Biosciences, San Jose, CA), CD4 (SK3; BD Biosciences), and CD8 (SK1; BD Biosciences). Cross-reactivity of these mAbs for the rhesus ma-

caque was determined using the method described previously (45). However, the observed cross-reactivity with IL-5, IL-10, and IL-13 is a new finding and has not been published previously.

HIV-1 env gp120-specific ELISA and ELISPOT assays

HIV-1 env gp120-specific IgG, IgM, and IgA Ab titers in plasma, saliva, nasal washes, as well as rectal and vaginal lavages were determined by ELISA, as described previously (15, 16). The HIV-1 env gp120-specific IgG, IgM, and IgA Ab-forming cells (AFCs) were also determined by ELISPOT assay, as described elsewhere (15, 16).

Cytokine-specific ELISPOT assay

The PBMCs or lymphoid cells from various tissues were cultured in 10% FCS containing RPMI 1640 (Mediatech) supplemented with HEPES buffer (10 mM), L-glutamine (2 mM), nonessential amino acid solution (10 ml/L), sodium pyruvate (10 mM), penicillin (100 U/ml), streptomycin (100 µg/ml), and gentamicin (80 µg/ml) (complete medium) with or without 5 µg/ml HIV-1 env gp120, 1 µg/ml anti-human CD28 (CD28.2; BD Biosciences), and anti-human CD49d (9F10; BD Biosciences) mAbs at 37°C with 5% CO₂. Nonadherent cells were harvested after 3 days of incubation and stained with anti-human CD3 and CD8 mAbs. The FACS Vantage (BD Biosciences) was used to sort out a subset of CD3⁺CD8⁻ T cells. The frequencies of CD4⁺ Th1- and Th2-type cytokine-producing cells were determined by using rhesus macaque cytokine-specific ELISPOT kits (UCyTech, Utrecht, The Netherlands).

In vitro HIV-1 neutralization assay

The diluted plasma or appropriate mucosal secretion was heat inactivated (56°C for 30 min) and incubated with 20 TCID₅₀ (50% tissue culture infective dose) units of HIV-1_{LAI} overnight at 4°C. This mixture was then cocultured with 1 × 10⁶ M8166 cells for 2 h (16, 46, 47). After being washed twice with PBS, the cells were cultured in complete medium for 4 days at 37°C. Following incubation, culture supernatants were subjected to Lumipulse (chemiluminescence enzyme immunoassay/full automatic analyzer; Fujirebio, Tokyo, Japan) for measurement of HIV p24. The results were expressed as the percent inhibition of p24 gag production in culture supernatants when compared with the cultures containing pre- or nonimmunized plasma or mucosal secretions (16, 46, 47).

Nerve growth factor-β1 (NGF-β1) production in macaque olfactory tissues

The nasal turbinate region of the olfactory tissues was obtained from each macaque at the time of sacrifice. At the termination of the study, the nasal turbinate was perfused with PBS at 25°C. This was followed by perfusion with 100 ml of Zamboni's fixative (4% paraformaldehyde, 15% picric acid) in 0.1 M phosphate buffer. The olfactory bulbs and turbinates were removed and placed in fresh 4% paraformaldehyde at 4°C overnight. The tissue was then transferred to a 30% sucrose solution at 4°C for 48 h to cryoprotect it before sectioning. The tissue was then frozen in OCT compound, and the frozen sections (6 µm) were placed on precoated microscope slides (10% BSA in saline). For staining of sections, all slides were pretreated with rabbit IgG Ab to block nonspecific binding, followed by a biotinylated rabbit anti-human NGF-β1 Ab (Chemicon International, Temecula, CA) used at a concentration of 2 µg. The Ab-stained sections were incubated at 4°C overnight. The slides were then rinsed in three changes of PBS for 2 min and then reacted with avidin-biotin conjugate for 30 min at 25°C. The tissues were rinsed three times with PBS, and then reacted with 3,3'-diaminobenzidine (Vector Laboratories, Burlingame, CA) for 5–10 min before being again rinsed three times and having sections counterstained with hematoxylin for 30 s. After being washed in distilled water, the slides were dehydrated in 100% alcohol and xylene. In some experiments, the anti-NGF-β1 Ab-stained sections were incubated with HRP-conjugated streptavidin-Alexa Fluor 488 (Molecular Probes, Eugene, OR). Sections were examined with a fluorescence microscope (BX50/BXFLA; Olympus, Tokyo, Japan) equipped with a digital image capture system (Olympus).

Statistics

The results are expressed as the mean ± SEM. Immunized NHP groups were compared with the controls using a Mann-Whitney *U* test with Statview II software (Abacus Concepts, Berkeley, CA) designed for Macintosh computers. A *p* value of <0.05 or less was considered significant.

Results

Plasma anti-gp120-specific Ab responses

In this study, we have assessed the mucosal adjuvanticity of mCT E112K in rhesus macaques nasally immunized with HIV-1 gp120. Eleven macaques were given 100 µg of gp120 by the nasal route. In addition to the gp120, five macaques were given two doses of mCT E112K as nasal adjuvant, two (Rh09 and Rh91) receiving a 25 µg dose and three (NHPs Rh16, Rh39, and Rh85) receiving a 100 µg dose. As a positive control, and because our previous research showed that nCT is a potent nasal adjuvant for NHPs (16), four other macaques (Rh07, Rh35, Rh60, and Rh88) were given 10 µg of nCT along with gp120. As a negative control, the two remaining macaques (Rh43 and Rh51) were given gp120 alone. The gp120-specific IgG and IgA Abs in plasma of individual macaques were sequentially assessed by an endpoint ELISA. As expected based upon our previous studies (16), significant levels of gp120-specific IgG Ab responses were detected in plasma of all macaques given gp120 with nCT (Fig. 1; $p < 0.01$). Interestingly, comparable gp120-specific IgG Ab responses were observed in macaques receiving 100 µg of mCT E112K as nasal adjuvant (Fig. 1; $p <$

0.01), while much lower levels of these responses were noted in macaques receiving 25 µg of mCT E112K as nasal adjuvant ($p > 0.1$). Furthermore, the group receiving 100 µg of mCT E112K showed comparable gp120-specific plasma IgA Ab responses to those receiving nCT as mucosal adjuvant. In contrast, the two macaques given gp120 alone or those receiving only 25 µg of mCT E112K showed low to undetectable IgA Ab responses. When gp120-specific plasma Ab responses were compared between the two groups given 25 or 100 µg of mCT E112K groups, the group given the higher dose showed greater IgG ($p < 0.01$) and IgA Ab responses than did the group given 25 µg of mCT E112K. Taken together, these results show that 100 µg of mCT E112K is an appropriate dose for inducing HIV-1 gp120-specific plasma Ab responses.

Induction of gp120-specific mucosal immune responses

The gp120-specific IgA and IgG Ab titers were assessed in the mucosal secretions (saliva; nasal, vaginal, and rectal lavages) of macaques given nasal gp120 and mCT. The peak titers of IgG and IgA Abs occurred 7 or 14 days after the last nasal immunization

Reciprocal Log₂ gp120-Specific IgG and IgA Ab Titers




FIGURE 1. HIV-1 gp120-specific plasma IgG (●) and IgA (○) Ab titers were determined by endpoint ELISA. Rhesus macaques were nasally immunized with 100 µg of gp120 alone (Rh43 and Rh51), 100 µg of gp120 and 10 µg of nCT (Rh07, Rh35, Rh60, and Rh88), 100 µg of gp120 and 25 µg of mCT E112K (Rh09 and Rh91), or 100 µg of gp120 and 100 µg of mCT E112K (Rh16, Rh39, and Rh85). The data shown are endpoint titers for each macaque. *, $p < 0.01$ for IgG titers.

Table I. *gp120-specific Ab responses in mucosal secretions of rhesus macaques given a nasal vaccine*

Nasally Immunized with			Anti-gp120-Specific Reciprocal Log ₂ Ab Titers ^a							
gp120	Adjuvant	Identification Number of Macaque	Saliva		Nasal washes		Vaginal washes		Rectal washes	
			IgA	IgG	IgA	IgG	IgA	IgG	IgA	IgG
100 (μg)	E112K (25 μg)	Rh09	<1 ^b	2	NA ^c	NA	<1	3	NA	NA
		Rh91	2	2	NA	NA	<1	<1	NA	NA
	E112K (100 μg)	Rh16	6	5	5	3	NA	NA	3	<1
		Rh39	8	7	5	4	NA	NA	2	3
		Rh85	4	6	4	<1	NA	NA	3	<1
100 (μg)	nCT (10 μg)	Rh60	6	6	NA	NA	2	6	NA	NA
		Rh88	2	<1	NA	NA	<1	4	NA	NA
		Rh07	7	7	7	4	NA	NA	3	<1
		Rh35	5	5	2	<1	NA	NA	<1	<1
		Rh51	<1	<1	NA	NA	<1	2	NA	NA
100 (μg)	None	Rh43	3	2	<1	<1	NA	NA	<1	<1

^a Saliva, nasal, vaginal, and rectal washes were collected 7 or 14 days after final immunization and were then subjected to gp120-specific ELISA.
^b Endpoint titers were expressed as the last dilution giving an OD₄₆₀ of 0.1 U above samples obtained from nonimmunized controls.
^c NA, Not available.

(Table I). The findings for mucosal secretions paralleled those for plasma described above, with a dose of 100 μg of mCT E112K inducing gp120-specific IgA and IgG Ab levels comparable to those seen in macaques receiving nCT, but with a dose of only 25 μg of mCT E112K failing to support induction of gp120-specific Ab responses (Table I). These findings further support the notion that 100 μg of mCT E112K is the optimal dose for nasal adjuvanticity. Furthermore, our results demonstrate that a nasal vaccine of HIV-1 gp120 and mCT E112K as mucosal adjuvant would be an effective regimen for induction of anti-HIV-1 immune responses in external secretions of NHPs.

Induction of gp120-specific AFCs in mucosal lymphoid tissues


The induction of gp120-specific Ab responses was further confirmed at the level of plasma cell AFC responses. Comparable numbers of HIV-1 gp120-specific IgA and IgG AFCs were seen in the nasal passages of macaques immunized with gp120 plus either the optimal dose of mCT E112K (Rh39) or nCT (Rh60). Similarly, the numbers of gp120-specific IgA AFCs in SMGs and intestinal LP of macaques given the optimal dose of mCT E112K were comparable to those seen in positive controls given nCT as mucosal adjuvant (Fig. 2). These findings show that nasally coad-

ministered mCT possesses adjuvant activity for the induction of gp120-specific AFCs in mucosal effector tissues.

gp120-specific CD4⁺ Th1 and Th2 cell responses

Because nasal mCT showed adjuvant activity in both mucosal and systemic lymphoid compartments, HIV-1 gp120-specific CD4⁺ Th1- and Th2-type responses were assessed using a cytokine-specific ELISPOT assay. When restimulated with gp120 in vitro, mononuclear cells from spleen and mesenteric lymph nodes (MLNs) of macaques immunized with gp120 and either mCT E112K or nCT induced both Th1 (IFN-γ)- and Th2-type (IL-4, IL-10, and IL-13) cytokine-producing CD4⁺ T cells (Fig. 3). Both the group given mCT E112K and that given nCT showed higher numbers of IL-4- and IL-13-producing CD4⁺ T cells in MLNs than those observed in the two macaques nasally immunized with gp120 alone. The nCT-immunized group exhibited higher numbers of IL-4- and IL-13-producing CD4⁺ T cells than did the mCT E112K-immunized macaques, but the latter group showed higher numbers of IL-10-producing CD4⁺ T cells were noted in their MLNs. A similar pattern of Th2-type cytokine production was seen in the spleens of these two groups of macaques. The IFN-γ-producing CD4⁺ T cells were also seen in both MLNs and spleens

FIGURE 2. The gp120-specific IgG and IgA AFCs in mucosal and systemic lymphoid tissues of rhesus macaques (Rh51, □; Rh60, ▤; Rh39, ■) were determined by ELISPOT assay. Mononuclear cells were isolated from NPs, SMGs, the LP of the gastrointestinal tract, MLNs; spleen; and PBMC 2 wk following the final immunization. The results shown are the mean AFCs/10⁶ cells ± SEM.






FIGURE 3. Th1 and Th2 cytokine production by gp120-stimulated CD4⁺ T cells isolated from spleens and MLNs of rhesus macaques (Rh43, Rh07, and Rh85). Lymphocytes were cultured with or without gp120 for 3 days. Nonadherent cells were harvested and stained with anti-human CD3 and CD8 mAbs. A subset of CD3⁺, CD8⁻ T cells was purified using flow cytometry. The purified CD4⁺ T cells were subjected to an array of macaque-specific cytokine (IFN- γ , IL-4, IL-5, IL-10, and IL-13) ELISPOT assays.

of macaques given either mCT E112K or nCT as mucosal adjuvant. Interestingly, the numbers of IFN- γ -producing CD4⁺ T cells in the MLNs of both groups were lower than those seen in the spleens. These results suggest that mCT as nasal adjuvant preferentially induces Ag-specific Th2-type cytokine-producing CD4⁺ T cells, while also somewhat enhancing the induction of Th1-type cytokine-producing CD4⁺ T cells.

HIV-1_{LAI}-neutralizing Abs in external secretions and plasma

It was important to examine whether gp120-specific Abs in external secretions or plasma induced in NHPs given nasal gp120 and mCT E112K as mucosal adjuvant possessed HIV-neutralizing activity. To assess neutralizing activity, we performed an in vitro neutralization assay using HIV-1_{LAI}. The plasma (1/10 dilution) from macaques given nasal gp120 plus mCT E112K showed ~75–90% inhibition of HIV-1_{LAI}, a significantly higher rate than that seen in control plasma samples from either naive macaques or

NHPs given gp120 only (Fig. 4A). Furthermore, the nasal lavages (1/10 dilution) from two rhesus macaques (Rh16 and Rh85) given nasal gp120 plus mCT E112K exhibited 35 and 55% inhibition of HIV-1_{LAI}, a rate of inhibition comparable to that seen in NHPs given nasal nCT as mucosal adjuvant. In contrast, control groups (naive macaques or those given gp120 alone) possessed little ability to inhibit HIV-1_{LAI} (<20%) (Fig. 4B). These results clearly show that nontoxic mCT E112K can be used as a mucosal adjuvant for the induction of HIV-1-specific neutralizing immunity in both external secretions and plasma.

Safety of mCT E112K when used as a nasal adjuvant in NHPs

To assess the threat of neuronal damage posed by nasal vaccines containing gp120 and mCT E112K, NGF- β 1 production in nasal turbinates of olfactory tissues was examined. Macaques given gp120 with nCT exhibited areas of intense NGF- β 1 production in the olfactory region, which was associated with neuronal damage




FIGURE 4. In vitro neutralization of HIV-1 was performed with a standard p24 release assay. The plasma (A) and nasal wash (B) samples were collected 2 wk after the final immunization. Samples were diluted 1/10 (■) or 1/100 (□) and were analyzed for the presence of neutralizing Abs against a homogenous laboratory strain (HIV-1_{LAI}). As controls, plasma samples were obtained from macaques before nasal immunization (preimmune sample). The results are the mean values of three separate assays.

and inhibition of apoptosis (Fig. 5C). In contrast, macaques given nasal gp120 plus mCT E112K (Fig. 5B) expressed very minimal levels of NGF- β 1, which were essentially the same as those seen in olfactory tissues taken from the macaques given nasal gp120 alone (Fig. 5A). These results indicate that mCT E112K, although as effective a mucosal adjuvant as nCT, possesses none of its toxicity for neuronal tissues. As a safe and potent mucosal adjuvant, mCT E112K could speed the development of a nasal HIV-1 vaccine in humans.

Discussion

This study clearly provides direct evidence that mCT E112K is an effective mucosal adjuvant for the induction of HIV-1-specific immunity in the NHP model. When used as a nasal adjuvant, mCT E112K induced gp120-specific Abs possessing HIV-neutralizing activity in both external secretions and plasma, but showed negligible toxicity for the CNS-associated tissues of rhesus macaques. In contrast, nCT elicited increases in NGF- β production, a major manifestation of CNS inflammation. Thus, our study is the first to provide evidence establishing the efficacy and safety of an adjuvant for use in higher mammals. Collectively, our findings convincingly demonstrate the potential of mCT E112K as a mucosal adjuvant in humans and suggest that it may be time to take the next step toward the development of nasal vaccines, including those for HIV-1, by beginning clinical trials.

Our previous studies have already shown the efficacy and safety of mCT E112K as a nasal adjuvant in the murine system (43, 47, 48). In our earlier studies, we established that nasal immunization with pneumococcal surface protein A or diphtheria toxoid plus mCT E112K elicited sufficient Ag-specific immune responses to provide protection after lethal challenge with either *Streptococcus pneumoniae* bacteria or diphtheria exotoxin (48, 49). Furthermore, nasal application of mCT together with protein Ags elicited both Ag-specific IgA and IgG Ab responses in mucosal and systemic lymphoid tissue compartments (43, 47, 48). Among the different forms of mutant toxin-based adjuvants, mCT E112K was shown to

be the safest and most effective in the murine model (41–43). However, until now, no studies assessing the mucosal adjuvanticity of different forms of toxin-based mutant adjuvants such as our mCT E112K had been performed in a large mammalian animal model, i.e., NHPs. Among the mammalian models, we chose the NHP experimental model as the most appropriate to and useful for the development of an HIV/AIDS mucosal vaccine.

AIDS is well known to be a sexually transmitted disease caused by HIV-1 infection via mucosal surfaces. The NHP experimental model of SIV infection has provided detailed evidence for the mucosal transmission of the virus, and has shown that the inhibition of its entry via the mucosa led to protection against disease development (50). Accordingly, an effective HIV/AIDS vaccine will be more readily developed if the potential of the common mucosal immune system is tapped, because mucosal immunization is known to induce effective protection against pathogens at mucosal surfaces as well as in lymphoid tissue compartments (37, 38, 51). Of note, our previous study showed that nasal immunization with SIV p55^{gag} plus nCT as mucosal adjuvant induced in vaginal secretions of rhesus macaques Ag-specific Ab responses with virus-specific neutralizing Ab activity. In the case of the NHP experimental model, our studies have shown that mucosal (both oral or nasal) immunization with SIV p55^{gag} plus nCT induced Ag-specific humoral and cellular immunity in both mucosal and systemic immune systems of rhesus macaques (15, 16, 52).

Despite its strong mucosal adjuvanticity, nCT is of little practical value as a mucosal adjuvant in humans because of its toxicity. Thus, much effort has been expended on the creation of genetically manipulated nontoxic mutants of CT that would retain adjuvanticity, but not toxicity. In the current study, we sought to examine the mucosal adjuvanticity of mCT E112K as nasal adjuvant when coadministered to rhesus macaques with HIV-1 gp120. In this study, we provide the first evidence that the nasal application of mCT E112K as a mucosal adjuvant effectively induces HIV-1 gp120-specific Ab responses in both mucosal and systemic lymphoid tissues of rhesus macaques. Furthermore, plasma and nasal




FIGURE 5. Detection of NGF- β 1 expression in olfactory bulbs of rhesus macaques nasally immunized with gp120 and either nCT or mCT E112K as mucosal adjuvant. The anti-NGF- β 1 Ab-stained sections were reacted with avidin-biotin conjugate, followed by 3,3'-diaminobenzidine (A–C), or incubated with HRP-conjugated streptavidin-Alexa Fluor 488 (D–F). C ($\times 40$) and F ($\times 100$), Show high expression of NGF- β 1 along neuronal tracts when rhesus macaques were given nCT and gp120. B ($\times 40$) and E ($\times 100$), Show tissues from a macaque given gp120 plus mCT E112K. A ($\times 40$) and D ($\times 100$), Illustrate tissues from a macaque given gp120 alone.

washes from macaques given nasal gp120 plus mCT E112K contained HIV-1_{LAT}-neutralizing Abs. These findings clearly demonstrate the efficacy of mCT E112K as a mucosal adjuvant and suggest its potential for use in trial vaccines in humans.

However, nCT and even some of its nontoxic mutant forms pose additional, more specialized dangers when administered via the nasal route, the route of choice for mucosal vaccines because of its efficacy at inducing Ag-specific immune responses. Nasal vaccines using either nCT or one of its nontoxic mutants as adjuvant risk entering the CNS because of the proximity of the olfactory nerves/epithelium and olfactory bulbs to the brain. This potential for neurotoxicity has been a major obstacle for the use of enterotoxin-based mucosal adjuvants, even nontoxic mutant forms, in humans via the nasal route.

Our own studies have shown the potential toxicity of nCT for the olfactory nerves/epithelium and olfactory bulbs (39). Thus, neuronal association of CT-B through GM1 ganglioside binding appears to preclude efficient clearing of these enterotoxin-based mucosal adjuvants and to cause extended accumulation of them in neuronal tissues associated with the olfactory tract (39). These results show that nasally administered CT derivatives retain some toxicity and are targeted to the CNS, posing a serious obstacle to human use. Indeed, recent reports showed that a human vaccine containing inactivated influenza and native labile toxin as an adjuvant resulted in a very high incidence of Bell's palsy (53, 54). These results strongly indicate that it is essential to develop a more safe and effective nasal vaccine for human use.

Our current findings demonstrate the promise of the nontoxic form of mCT E112K as a safe and effective mucosal adjuvant and so point the way to the development of better nasal vaccines. The nontoxic form of mCT E112K did not elicit any increase in NGF- β expression by the olfactory tissues of NHPs. Only minimal NGF- β synthesis, comparable to that seen in NHP given nasal gp120 alone, was detected in the olfactory CNS tissues of rhesus macaques given nasal mCT E112K as nasal adjuvant.

Our previous study showed that nasal immunization with p55^{gag} plus nCT induced p55^{gag}-specific T cell responses in both mucosal and systemic lymphoid tissue compartments (16). Thus, it was shown that both IFN- γ and IL-2 (Th1-type) expression as well as IL-5, IL-6, and IL-10 (Th2-type) production were seen in Ag-stimulated CD4⁺ T cells isolated from NHPs given nasal p55^{gag} and nCT. In this regard, our current study has shown that both Th1 (IFN- γ)- and Th2 (IL-10 and IL-13)-type cytokine-producing CD4⁺ T cells were present in the MLNs and spleens of rhesus macaques given either mCT E112K or nCT as a nasal adjuvant. Although the viral Ags used in the current study are different from those in the previous report, our results also showed that mCT E112K provided adjuvanticity in NHPs through the generation of both Th1- and Th2-type cytokine responses by CD4⁺ T cells. Induction of IFN- γ -producing CD4⁺ T cells by nasally coadministered mCT E112K may be an additional benefit because it may lead to the generation of Ag-specific cell-mediated immunity responses. In viral infections including HIV and SIV, CTL activity has been shown to be of central importance for host defense and to correlate well with IFN- γ production (44). In this regard, we postulate that nasally coadministered mCT E112K would also induce CTL activity in various mucosal tissues. Confirming this prediction, rhesus macaques given nasal nCT as mucosal adjuvant showed SIV-specific CTL activity (16). We are currently testing Ag-specific CTL activity in macaques given nasal mCT E112K as mucosal adjuvant.

In conclusion, the current study has provided significant new information for a potential human phase I clinical trial using the nontoxic form of toxin mucosal adjuvant mCT E112K. Thus, nasal

immunization of rhesus macaques with gp120 and mCT E112K resulted in the induction of Ab-neutralizing immunity against HIV-1 by inducing gp120-specific IgA and IgG Abs in both mucosal and systemic lymphoid tissue compartments, respectively. Furthermore, the safety of nasal mCT E112K was confirmed by the lack of CNS damage in this NHP model. This important new evidence supports the candidacy of mCT E112K as a potentially important mucosal adjuvant for use in humans.

Acknowledgments

We thank Dr. Kimberly K. McGhee for editorial comments on this manuscript. We also thank Sheila D. Turner for the final preparation of the paper.

References

- Alexander, N. J. 1990. Sexual transmission of human immunodeficiency virus: virus entry into the male and female genital tract. *World Health Organization, Global Program on Acquired Immune Deficiency Syndrome. Fertil. Steril.* 54:1.
- De Schryver, A., and A. Meheus. 1990. Epidemiology of sexually transmitted diseases: the global picture. *Bull. W. H. O.* 68:639.
- Hospedales, J. 1989. Heterosexual spread of HIV infection. *Rev. Infect. Dis.* 1:663.
- Mazzoli, S., D. Trabattini, S. Lo Caputo, S. Piconi, C. Ble, F. Meacci, S. Ruzzante, A. Salvi, F. Semplici, R. Longhi, et al. 1997. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. *Nat. Med.* 3:1250.
- Kaul, R., D. Trabattini, J. J. Bwayo, D. Arienti, A. Zagliani, F. M. Mwangi, C. Kariuki, B. N. Ngugi, K. S. MacDonald, T. B. Ball, et al. 1999. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. *AIDS* 13:23.
- Devito, C., J. Hinkula, R. Kaul, L. Lopalco, J. J. Bwayo, F. Plummer, M. Clerici, and K. Brolden. 2000. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. *AIDS* 14:1917.
- Kaul, R., F. Plummer, M. Clerici, M. Bomsel, L. Lopalco, and K. Brolden. 2001. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. *AIDS* 15:431.
- Brandtzaeg, P. 1989. Overview of the mucosal immune system. *Curr. Top. Microbiol. Immunol.* 146:13.
- Lee, S. H., P. M. Starkey, and S. Gordon. 1985. Quantitative analysis of total macrophage content in adult mouse tissues: immunohistochemical studies with monoclonal antibody F4/80. *J. Exp. Med.* 161:475.
- Smith, P. D., G. Meng, G. M. Shaw, and L. Li. 1997. Infection of gastrointestinal tract macrophages by HIV-1. *J. Leukocyte Biol.* 62:72.
- Lehner, T., L. A. Bergmeier, C. Panagiotidi, L. Tao, R. Brookes, L. S. Klavinskis, P. Walker, J. Walker, R. G. Ward, L. Hussain, et al. 1992. Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. *Science* 258:1365.
- Lehner, T., R. Brookes, C. Panagiotidi, L. Tao, L. S. Klavinskis, J. Walker, P. Walker, R. Ward, L. Hussain, J. H. Gearing, et al. 1993. T- and B-cell functions and epitope expression in nonhuman primates immunized with simian immunodeficiency virus antigen by the rectal route. *Proc. Natl. Acad. Sci. USA* 90:8638.
- Lehner, T., L. Tao, C. Panagiotidi, L. S. Klavinskis, R. Brookes, L. Hussain, N. Meyers, S. E. Adams, A. J. Gearing, and L. A. Bergmeier. 1994. Mucosal model of genital immunization in male rhesus macaques with a recombinant simian immunodeficiency virus p27 antigen. *J. Virol.* 68:1624.
- Lehner, T., Y. Wang, M. Cranage, L. A. Bergmeier, E. Mitchell, L. Tao, G. Hall, M. Dennis, N. Cook, R. Brookes, et al. 1996. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. *Nat. Med.* 2:767.
- Kubota, M., C. J. Miller, K. Imaoka, S. Kawabata, K. Fujihashi, J. R. McGhee, and H. Kiyono. 1997. Oral immunization with simian immunodeficiency virus p55^{gag} and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates. *J. Immunol.* 158:5321.
- Imaoka, K., C. J. Miller, M. Kubota, M. B. McChesney, B. Lohman, M. Yamamoto, K. Fujihashi, K. Someya, M. Honda, J. R. McGhee, and H. Kiyono. 1998. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55^{gag} and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. *J. Immunol.* 161:5952.
- Belyakov, I. M., Z. Hei, B. Kelsall, V. A. Kuznetsov, J. D. Ahlers, J. Nacsa, D. I. Watkins, T. M. Allen, A. Sette, J. Altman, et al. 2001. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. *Nat. Med.* 7:1320.
- Lohman, B. L., M. B. McChesney, C. J. Miller, M. Otsyula, C. J. Berardi, and M. L. Marthas. 1994. Mucosal immunization with a live, virulence-attenuated simian immunodeficiency virus (SIV) vaccine elicits antiviral cytotoxic T lymphocytes and antibodies in rhesus macaques. *J. Med. Primatol.* 23:95.
- Quessada-Rolander, M., B. Makitalo, R. Thorstensson, Y. J. Zhang, E. Castanos-Velez, G. Biberfeld, and P. Putkonen. 1996. Protection against mucosal SIVm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. *AIDS Res. Hum. Retroviruses* 12:993.
- Nilsson, C., B. Makitalo, R. Thorstensson, S. Norley, D. Binninger-Schinzler, M. Cranage, E. Rud, G. Biberfeld, and P. Putkonen. 1998. Live attenuated simian

- immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. *AIDS* 12:2261.
21. Johnson, R. P., J. D. Lifson, S. C. Czajak, K. S. Cole, K. H. Manson, R. Glickman, J. Yang, D. C. Montefiori, R. Montelaro, M. S. Wyand, and R. C. Desrosiers. 1999. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. *J. Virol.* 73:4952.
 22. Enose, Y., M. Ui, A. Miyake, H. Suzuki, H. Uesaka, T. Kuwata, J. Kunisawa, H. Kiyono, H. Takahashi, T. Miura, and M. Hayami. 2002. Protection by intranasal immunization of a *nef*-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV. *Virology* 298:306.
 23. Shacklett, B. L., K. E. Shaw, L. A. Adamson, D. T. Wilkens, C. A. Cox, D. C. Montefiori, M. B. Gardner, P. Sonigo, and P. A. Luciw. 2002. Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251. *J. Virol.* 76:11365.
 24. Buge, S. L., E. Richardson, S. Alipanah, P. Markham, S. Cheng, N. Kalyan, C. J. Miller, M. Lubeck, S. Udem, J. Eldridge, and M. Robert-Guroff. 1997. An adenovirus-simian immunodeficiency virus *env* vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. *J. Virol.* 71:8531.
 25. Benson, J., C. Chougniet, M. Robert-Guroff, D. Montefiori, P. Markham, G. Shearer, R. C. Gallo, M. Cranage, E. Paoletti, K. Limbach, et al. 1998. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. *J. Virol.* 72:4170.
 26. Crotty, S., B. L. Lohman, F. X. Lu, S. Tang, C. J. Miller, and R. Andino. 1999. Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity. *J. Virol.* 73:9485.
 27. Leung, N. J., A. Aldovini, R. Young, M. A. Jarvis, J. M. Smith, D. Meyer, D. E. Anderson, M. P. Carlos, M. B. Gardner, and J. V. Torres. 2000. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. *Virology* 268:94.
 28. Crotty, S., C. J. Miller, B. L. Lohman, M. R. Neagu, L. Compton, D. Lu, F. X. Lu, L. Fritts, J. D. Lifson, and R. Andino. 2001. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. *J. Virol.* 75:7435.
 29. Izumi, Y., Y. Ami, K. Matsuo, K. Someya, T. Sata, N. Yamamoto, and M. Honda. 2003. Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus *gag* controls highly pathogenic simian-human immunodeficiency virus in monkeys. *J. Virol.* 77:13248.
 30. Wang, S. W., P. A. Kozlowski, G. Schmelz, K. Manson, M. S. Wyand, R. Glickman, D. Montefiori, J. D. Lifson, R. P. Johnson, M. R. Neutra, and A. Aldovini. 2000. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. *J. Virol.* 74:10514.
 31. Gorelick, R. J., J. D. Lifson, J. L. Yovandich, J. L. Rossio, M. Piatak, Jr., A. J. Scarsello, W. B. Knott, J. W. Bess, Jr., B. A. Fisher, B. M. Flynn, et al. 2000. Mucosal challenge of *Macaca nemestrina* with simian immunodeficiency virus (SIV) following SIV nucleocapsid mutant DNA vaccination. *J. Med. Primatol.* 29:209.
 32. Fuller, D. H., P. A. Rajakumar, L. A. Wilson, A. M. Trichel, J. T. Fuller, T. Shipley, M. S. Wu, K. Weis, C. R. Rinaldo, J. R. Haynes, and M. Murphy-Corb. 2002. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. *J. Virol.* 76:3309.
 33. Muthumani, K., M. Bagarazzi, D. Conway, D. S. Hwang, K. Manson, R. Ciccarelli, Z. Israel, D. C. Montefiori, K. Ugen, N. Miller, et al. 2003. A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduces viral loads after pathogenic intrarectal SIV251 challenge in rhesus macaques. *Vaccine* 21:629.
 34. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, et al. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. *Science* 292:69.
 35. Amara, R. R., J. M. Smith, S. I. Staprans, D. C. Montefiori, F. Villinger, J. D. Altman, S. P. O'Neil, N. L. Kozyr, Y. Xu, L. S. Wyatt, et al. 2002. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. *J. Virol.* 76:6138.
 36. Dale, C. J., X. S. Liu, R. De Rose, D. F. Purcell, J. Anderson, Y. Xu, G. R. Leggett, I. H. Frazer, and S. J. Kent. 2002. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. *Virology* 301:176.
 37. McGhee, J. R., and H. Kiyono. 1998. The mucosal immune system. In *Fundamental Immunology*, 4th Ed. W. E. Paul, ed. Academic Press, San Diego, p. 909.
 38. Fujihashi, K., and J. R. McGhee. The mucosal immune response. In *Topley and Wilson's Microbiology and Microbial Infections*. S. H. E. Kaufmann, ed. Edward Arnold, London, *In press*.
 39. Van Ginkel, F. W., R. J. Jackson, Y. Yuki, and J. R. McGhee. 2000. The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. *J. Immunol.* 165:4778.
 40. Xu-Amano, J., H. Kiyono, R. J. Jackson, H. F. Staats, K. Fujihashi, P. D. Burrows, C. O. Elson, S. Pillai, and J. R. McGhee. 1993. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. *J. Exp. Med.* 178:1309.
 41. Okahashi, N., M. Yamamoto, J. L. Van Cott, S. N. Chatfield, M. Roberts, H. Bluetmann, T. Hiroi, H. Kiyono, and J. R. McGhee. 1996. Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant *Salmonella* strain or cholera toxin reveals that CD4⁺ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. *Infect. Immun.* 64:1516.
 42. Yamamoto, S., Y. Takeda, M. Yamamoto, H. Kurazono, K. Imaoka, M. Yamamoto, K. Fujihashi, M. Noda, H. Kiyono, and J. R. McGhee. 1997. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. *J. Exp. Med.* 185:1203.
 43. Yamamoto, S., H. Kiyono, M. Yamamoto, K. Imaoka, K. Fujihashi, F. W. van Ginkel, M. Noda, Y. Takeda, and J. R. McGhee. 1997. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. *Proc. Natl. Acad. Sci. USA* 94:5267.
 44. Di Fabio, S., L. N. Mbawuke, H. Kiyono, K. Fujihashi, R. B. Couch, and J. R. McGhee. 1994. Quantitation of human influenza virus-specific cytotoxic T lymphocytes: correlation of cytotoxicity and increased numbers of IFN- γ producing CD8⁺ T cells. *Int. Immunol.* 6:11.
 45. Yoshino, N., Y. Ami, K. Terao, F. Tashiro, and M. Honda. 2000. Upgrading of flow cytometric analysis for absolute counts, cytokines and other antigenic molecules of cynomolgus monkeys (*Macaca fascicularis*) by using anti-human cross-reactive antibodies. *Exp. Anim.* 49:97.
 46. Honda, M., K. Matsuo, T. Nakasone, Y. Okamoto, H. Yoshizaki, K. Kitamura, W. Sugura, K. Watanabe, Y. Fukushima, S. Haga, et al. 1995. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant *Mycobacterium bovis* bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. *Proc. Natl. Acad. Sci. USA* 92:10693.
 47. Gorny, M. K., A. J. Conley, S. Karwowska, A. Buchbinder, J. Y. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. *J. Virol.* 66:7538.
 48. Yamamoto, M., D. E. Briles, S. Yamamoto, M. Ohmura, H. Kiyono, and J. R. McGhee. 1998. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. *J. Immunol.* 161:4115.
 49. Ohmura, M., M. Yamamoto, H. Kiyono, K. Fujihashi, Y. Takeda, and J. R. McGhee. 2001. Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin. *Vaccine* 20:756.
 50. Müller, C. J. 1998. Localization of simian immunodeficiency virus-infected cells in the genital tract of male and female rhesus macaques. *J. Reprod. Immunol.* 41:331.
 51. McGhee, J. R., J. Xu-Amano, C. J. Miller, R. J. Jackson, K. Fujihashi, H. F. Staats, and H. Kiyono. 1994. The common mucosal immune system: from basic principles to enteric vaccines with relevance for the female reproductive tract. *Reprod. Fertil. Dev.* 6:369.
 52. McGhee, J. R., H. Kiyono, M. Kubota, S. Kawabata, C. J. Miller, T. Lehner, K. Imaoka, and K. Fujihashi. 1999. Mucosal Th1- versus Th2-type responses for antibody- or cell-mediated immunity to simian immunodeficiency virus in rhesus macaques. *J. Infect. Dis.* 179:5480.
 53. Couch, R. B. 2004. Nasal vaccination, *Escherichia coli* enterotoxin, and Bell's palsy. *N. Engl. J. Med.* 350:860.
 54. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. *N. Engl. J. Med.* 350:896.

Vaccination of Rhesus Macaques with Recombinant *Mycobacterium bovis* Bacillus Calmette-Guérin Env V3 Elicits Neutralizing Antibody-Mediated Protection against Simian-Human Immunodeficiency Virus with a Homologous but Not a Heterologous V3 Motif

Kenji Someya,^{1*} Dayaraj Cecilia,² Yasushi Ami,³ Tadashi Nakasone,¹ Kazuhiro Matsuo,^{1,4}
Sherri Burda,² Hiroshi Yamamoto,⁵ Naoto Yoshino,⁶ Masahiko Kaizu,^{1,4} Shuji Ando,¹
Kenji Okuda,⁷ Susan Zolla-Pazner,² Shudo Yamazaki,¹ Naoki Yamamoto,¹
and Mitsuo Honda^{1,4}

AIDS Research Center¹ and Division of Experimental Animal Research,³ National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Yokohama City University, Kanazawa-ku, Yokohama,⁷ Japan Science and Technology Corporation, Kawaguchi, Saitama,⁴ Toyama Medical Pharmaceutical University, Toyama, Toyama,⁵ and Iwate Medical University, Morioka, Iwate,⁶ Japan, and New York University Medical Center, New York, New York²

Received 25 June 2004/Accepted 23 September 2004

Although the correlates of vaccine-induced protection against human immunodeficiency virus type 1 (HIV-1) are not fully known, it is presumed that neutralizing antibodies (NAb) play a role in controlling virus infection. In this study, we examined immune responses elicited in rhesus macaques following vaccination with recombinant *Mycobacterium bovis* bacillus Calmette-Guérin expressing an HIV-1 Env V3 antigen (rBCG Env V3). We also determined the effect of vaccination on protection against challenge with either a simian-human immunodeficiency virus (SHIV-MN) or a highly pathogenic SHIV strain (SHIV-89.6PD). Immunization with rBCG Env V3 elicited significant levels of NAb for the 24 weeks tested that were predominantly HIV-1 type specific. Sera from the immunized macaques neutralized primary HIV-1 isolates in vitro, including HIV-1_{BZ167/X4}, HIV-1_{SF2/X4}, HIV-1_{CI2/X4}, and, to a lesser extent, HIV-1_{MNP/X4}, all of which contain a V3 sequence homologous to that of rBCG Env V3. In contrast, neutralization was not observed against HIV-1_{SF33/X4}, which has a heterologous V3 sequence, nor was it found against primary HIV-1 R5 isolates from either clade A or B. Furthermore, the viral load in the vaccinated macaques was significantly reduced following low-dose challenge with SHIV-MN, and early plasma viremia was markedly decreased after high-dose SHIV-MN challenge. In contrast, replication of pathogenic SHIV-89.6PD was not affected by vaccination in any of the macaques. Thus, we have shown that immunization with an rBCG Env V3 vaccine elicits a strong, type-specific V3 NAb response in rhesus macaques. While this response was not sufficient to provide protection against a pathogenic SHIV challenge, it was able to significantly reduce the viral load in macaques following challenge with a nonpathogenic SHIV. These observations suggest that rBCG vectors have the potential to deliver an appropriate virus immunogen for desirable immune elicitation.

Development of a preventive vaccine against human immunodeficiency virus type 1 (HIV-1) is urgently needed to control the spread of the virus worldwide. Although the immunological parameters that correlate with protective immunity against natural infection with HIV-1 are not fully known, it is assumed that a preventive vaccine must elicit potent, broadly reactive immunity against divergent strains of HIV-1 (25, 36, 42). Several recent studies have demonstrated that induction of virus-specific T-cell responses can confer protective immunity in nonhuman primate models, and these responses may also play a role in controlling HIV-1 replication in humans (6, 18, 19, 31, 33, 34, 38, 45, 48). Vaccine constructs containing viral *env* genes, in addition to *gag* and *pol*, have been shown to effec-

tively control replication of challenge viruses (2, 5, 10), suggesting that neutralizing antibody (NAb) responses might also contribute to protection against pathogenic infection or disease progression. Passive transfer of serum immunoglobulin from chimpanzees experimentally infected with several different HIV-1 isolates has been shown to block the establishment of a simian immunodeficiency virus (SIV)-HIV chimeric simian-human immunodeficiency virus (SHIV) infection in pig-tailed macaques (37, 46). It is not known, however, whether vaccines that actively elicit a potent NAb response can provide protection in nonhuman primates challenged with SHIV.

Previously, we demonstrated that recombinant *Mycobacterium bovis* bacillus Calmette-Guérin (rBCG), which secretes a chimeric protein consisting of the V3-neutralizing epitope of HIV-1 and α -antigen (rBCG Env V3), can induce HIV-1-specific NAb in a small-animal model (9, 15, 16). BCG was selected as a vaccine vehicle because it has several characteristics that are considered efficacious for developing a candidate

* Corresponding author. Mailing address: AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo 162-8640, Japan. Phone: 81-3-5285-1111, ext. 2737. Fax: 81-3-5285-1183. E-mail: someyan@nih.go.jp.

HIV-1 vaccine (1, 49), including the ability to induce long-lasting immune responses (7). It is generally accepted that a candidate vaccine against HIV-1 must also be easily administered and affordable in developing countries, and it must be compatible with other commonly administered vaccines (35). If effective, a BCG-based recombinant HIV-1 (rBCG-HIV-1) vaccine would fulfill many of these critical requirements.

Results using other vaccine modalities, in particular, live attenuated SIV vaccines, have raised concerns about the potential for reversion to pathogenicity (3, 4), suggesting that many SIV strains may be potentially virulent. In this study, we used two distinct strains of challenge virus: SHIV-MN (29), which contains V3 sequences homologous to rBCG Env V3, and SHIV-89.6PD (12, 20, 28, 41), which is heterologous in the V3 region and highly pathogenic. We examined whether vaccination with rBCG Env V3 could effectively elicit NAb responses in rhesus macaques and whether it might effectively induce protective immunity against challenge with either SHIV-MN or SHIV-89.6PD.

MATERIALS AND METHODS

Animals. The macaques (*Macaca mulatta*) used in this study originated from China and were purchased through Japan SLC Ltd., Shizuoka, Japan. The animals were maintained according to standard operating procedures established for the evaluation of human vaccines at the Tsukuba Primate Center, National Institute of Infectious Diseases, Tsukuba, Ibaragi, Japan. The study was conducted in the P3 facility for monkeys in the Murayama Branch, National Institute of Infectious Diseases, Musashimurayama, Tokyo, Japan, and in accordance with requirements specified in the laboratory biosafety manual of the World Health Organization.

Construction of the rBCG Env V3 immunogen. rBCG substrain Tokyo was produced by transfection of BCG-Tokyo 172 cells with plasmid pSQ246 as described previously (21, 22, 30). The XhoI site of this plasmid was used to insert a mycobacterial codon-optimized DNA fragment encoding 19 amino acids of the Japanese HIV-1 V3 consensus sequence (NTRKSIHIGPGRGFYATGS), which has a neutralization sequence identical to that of HIV-1_{MN} (16, 23, 39, 52). The resulting rBCG vector was designated rBCG Env V3. By semiquantitation of a chimeric protein consisting of the V3 peptides and α -K protein (9), the concentration of the secreted protein was estimated to range from 1 to 3 μ g/ml in the culture filtrate of rBCG Env V3 (data not shown).

Viruses. Viruses used in challenge experiments were kindly provided by Y. Lu, Harvard AIDS Institute, Cambridge, Mass. The SHIV-MN virus stock was prepared in concanavalin A-activated macaque peripheral blood mononuclear cells (PBMC) from normal animals, and the amount of virus was quantified by SIV p27 antigen enzyme-linked immunosorbent assay (ELISA) (Coulter Co., Hialeah, Fla.). The tissue culture infective dose (TCID) of the stock was measured on CEMx174 cells (AIDS Research and Reference Reagent Program, National Institutes of Health, Rockville, Md.). Stocks of HIV-1_{MN} and HIV-1_{IIB} (AIDS Research and Reference Reagent Program) were prepared by propagating 100 50% TCID (TCID₅₀) of each virus in phytohemagglutinin-activated normal human PBMC, as described previously (17). The primary isolate, HIV-1_{MNp}, was kindly provided by J. Sullivan, University of Massachusetts Medical School, Worcester, Mass. All other viruses were obtained from the AIDS Research and Reference Reagent Program. Cell-free virus stocks were stored at -130°C until they were used.

V3-specific ELISA. HIV-1 V3 peptide-based ELISAs were used for titration and quantification of serum antibodies for detection as described previously (14). In brief, 96-well ELISA plates (MaxiSorp; Nunc A/S, Roskilde, Denmark) were coated with 100 μ l of peptide MN (DKRIHIGPGRGFYTT) in 50 mM carbonate buffer (pH 9.3) at 5 μ g/ml overnight at 4°C . The wells were washed and treated with 5% nonfat milk in phosphate-buffered saline for 1 h at 37°C . Duplicate samples containing either control or test macaque serum at appropriate dilutions were then added at 100 μ l/well, and the plates were incubated for 1 h at 37°C . The wells were washed and incubated with a detection antibody solution consisting of peroxidase-conjugated goat anti-monkey immunoglobulin G (IgG) antibody (EY laboratories Inc., San Mateo, Calif.) at 100 μ l/well for 1 h at 37°C . After final washes with 0.05% Tween-20-phosphate-buffered saline

(PBST), peroxidase substrate was added, and the reaction was stopped by the addition of 0.5 M H₂SO₄.

IFN- γ ELISPOT assay. Enzyme-linked immunosorbent (ELISPOT) assays were performed using the method developed by Mothe and Watkins of the Wisconsin University Primate Center and described elsewhere (18, 33). In brief, 96-well flat-bottom plates (U-CyTech-BV, Utrecht, The Netherlands) were coated with anti-gamma interferon (IFN- γ) monoclonal antibody before being washed with PBST and blocked with bovine serum albumin. Freshly isolated PBMC were mixed with either concanavalin A or 2 μ M V3 peptide and were then incubated for 16 h at 37°C in 5% CO₂ in anti-IFN- γ -coated plates. Once the plates had been washed, rabbit anti-IFN- γ polyclonal biotinylated detector antibodies were added, and the plates were incubated. Gold-labeled anti-biotin IgG solution (U-CyTech-BV) was added to the plates after they were washed with PBST. The plates were then incubated for 1 h at 37°C . Developed wells were imaged, and spot-forming cells (SFC) were counted using the KS ELISPOT compact system (Carl Zeiss, Oberkochen, Germany). An SFC was defined as a large black spot with a fuzzy border (33).

In vitro virus neutralization assays. GHOST cell neutralization assays were performed as previously described (8). Briefly, GHOST cells expressing either CXCR4 or CCR5 were used as targets for HIV-1 infection (50, 54). The cells were analyzed by FACSCalibur flow cytometry (Becton Dickinson, San Jose, Calif.), and 15,000 events were scored. The mean number of fluorescent GHOST cells determined from negative controls plus 2 standard deviations was considered the cutoff for a positive sample. Purified human immunoglobulin (Nihon Pharmaceutical Co., Tokyo, Japan) and saline were included as additional controls.

M8166 cell-based virus neutralization assays were also performed as described previously (16, 47). In brief, the in vitro neutralization activity of purified macaque IgG was determined using 100 TCID₅₀ of either HIV-1_{MN} or SHIV-MN in cultures of M8166 cells. The results were compared with parallel cultures to which preimmune serum IgG was added. Neutralization was expressed as percent inhibition of HIV-1 p24 or SIV p27 antigen production in the culture supernatant. Purified normal macaque IgG was used as a control.

Quantification of cell-associated viral load. Levels of cell-associated virus were quantified by limiting dilution of PBMC (from 10⁶ to 1 cells), and the virus was cocultured with M8166 cells as described previously (17). Virus released into the culture supernatant was measured by SIV p27 antigen ELISA (Coulter). The smallest number of PBMC required to produce a positive culture was considered the end point, and the titer of infectious virus was expressed as TCID₅₀ per 10⁶ PBMC.

PCR detection of proviral HIV-1 infection of rhesus macaques. PBMC with SHIV were detected by DNA PCR using a primer pair that spans the C2-V3 sequence of HIV-1_{IIB}, followed by Southern blotting with an SE1 probe, 5'-G CAGAAGAAGAGGTAGTAATTAGAT-3' (nucleotides 7019 to 7043) (47). The positions of the oligonucleotides are numbered relative to the HIV-1_{HXB2} isolate in the ENTREZ database (National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Md.). Viral DNA was quantified by comparison with standards derived from 8E5/LAV cells, which contain one copy of HIV-1 proviral DNA per cell (AIDS Research and Reference Reagent Program).

Competitive PCR quantitation of SHIV RNA in plasma. Quantitative, competitive reverse transcription-PCR was performed using a competitor RNA and a DNA template as previously described (18, 32, 44). The detection limit of this assay was 500 RNA copies/ml in monkey plasma (18, 32).

Sequencing of HIV-1 Env C2-V3 sequence. To determine the sequence of the HIV-1 Env C2-V3 region, mRNA was extracted from stock virus and cDNA was synthesized using a Micro-FastTrack version 2.0 kit (Invitrogen, Carlsbad, Calif.) and a cDNA cycle kit (Invitrogen) according to the manufacturer's instructions. The PCR products were cloned into a pCR II vector with a dual promoter using a TA cloning kit (Invitrogen) (47). Sequence analysis was performed using a Big Dye terminator cycle-sequencing FS kit (Perkin-Elmer, Foster City, Calif.) and automated ABI 310 sequencer (Perkin-Elmer) with Sp6 and T7 sequence primers (Invitrogen). Sequence data were compared with published HIV-1 sequences in GenBank (National Center for Biotechnology Information, National Institutes of Health).

Statistical analysis. Calculations of the geometric mean \pm standard deviation (SD) were carried out with a microcomputer. Significance was defined as a *P* value of <0.05 .

RESULTS

Vaccination protocol. Twenty-four male rhesus macaques (R-01 through R-24) were enrolled in the study. Of these, 15 were subcutaneously immunized for 24 weeks with 10 mg of




FIG. 1. Schematic representation of the experimental protocol for immunization of rhesus macaques with rBCG Env V3 and challenge with either SHIV-MN or SHIV-89.6PD. A total of 24 macaques were assigned to either the rBCG Env V3 vaccine or rBCG vector control group. The animals each received a single subcutaneous injection and were then split into three groups prior to challenge with either low-dose SHIV-MN, high-dose SHIV-MN, or SHIV-98.6PD.

rBCG Env V3 (16), which expresses and secretes a chimeric protein consisting of α -antigen and the Env V3 region of HIV-1_{MN}. The remaining nine macaques were immunized by the same route and with the same dose of rBCG α -antigen and served as vector controls. All macaques inoculated with rBCG Env V3 remained in good health following vaccination. Three of the 15 immunized macaques experienced transient redness with slight erosion localized at the injection site; however, the reaction spontaneously resolved within 3 months. Following immunization, the 24 macaques were divided into three groups, each group consisting of five immunized animals and three vector controls. The macaques within each group received an intravenous challenge with either SHIV-MN (20 or 200 TCID₅₀) or SHIV-89.6PD (20 TCID₅₀) (Fig. 1).

Vaccine-induced HIV-specific immune responses following rBCG Env V3 immunization. (i) **Neutralizing antibodies.** As described above, 15 rhesus macaques were vaccinated with a single subcutaneous inoculation of 10 mg of rBCG Env V3. Induction of HIV-1-specific immunity was measured 24 weeks later in blood samples obtained pre- and postvaccination. All 15 immunized macaques exhibited HIV-1 Env V3 peptide-binding antibody activity by ELISA at serum dilutions ranging from 1:640 to 1:10,240 (Fig. 2). Antibody responses were monophasic, peaking at 4 to 6 weeks and then gradually declining. Serum samples obtained from naïve macaques were consistently negative by ELISA, while postvaccination sera did not react with a control fusion peptide of HIV gp41 (data not shown).

Antibodies were purified from the macaque sera to remove factors that might interfere with certain bioassays (51). The purified antibodies were then tested in vitro for the ability to neutralize SHIV-MN infection in M1866 cells (Fig. 3). Antibodies induced in macaques vaccinated with rBCG Env V3 strongly neutralized both the challenge SHIV-MN (grown in rhesus PBMC) and a T-cell line-adapted (TCLA) laboratory strain, HIV-1_{MN}. A mean 50% inhibitory concentration (IC₅₀) of 0.05 to 0.5 μ g/ml was measured against SHIV-MN, and a mean IC₉₀ of \sim 3.0 μ g/ml was observed against HIV-1_{MN}. Neutralizing activity was detected in serum samples obtained 4 to 6 weeks after vaccination and was maintained for at least 24 weeks. Preimmune serum IgG from nine macaques immunized with vector alone, and IgG from three additional naïve macaques (data not shown), did not neutralize either virus.

(ii) **Neutralization responses against primary HIV-1 isolates.** To further assess the specificity of antibodies in immune sera, neutralizing activity was evaluated against a panel of seven primary HIV-1 isolates using GHOST cells expressing either CCR5 or CXCR4 (Table 1). Purified IgG from macaques in each of the three immunization groups was able to effectively neutralize HIV-1_{BZ167/X4}, HIV-1_{SF2/X4}, and HIV-1_{CI2/X4} (Table 1 and Fig. 4), with mean IC₅₀ values of 5 to 7, 4 to 7, and 5 to 15 μ g/ml, respectively. By comparison, neutralization of HIV-1_{MNP/X4} required \sim 10-fold more serum IgG, with a mean IC₅₀ of 50 μ g/ml. Three additional isolates, HIV-1_{SF33/X4}, HIV-1_{SF33/R5}, and the clade A isolate HIV-1_{VI313/R5},




FIG. 2. Serum anti-V3 antibody titers determined by peptide-based ELISA. Preimmune and immune sera from macaques inoculated with rBCG Env V3 were collected and stored at -80°C until they were used. Sera from naive macaques were used as controls. Data using preimmune sera were within the control levels (data not shown). The results are expressed as the means \pm SD of four independent assays.

were not neutralized with serum IgG concentrations up to 50 $\mu\text{g/ml}$ (Table 1). Preimmune sera had no neutralizing activity against any of the isolates. Thus, antibodies present in sera from the immunized macaques were able to neutralize primary HIV-1 isolates, including HIV-1_{BZ167}, HIV-1_{SF2}, and HIV-1_{CI2}, in assays using GHOST cells that express CXCR4 with 10- to 50-fold-higher sensitivity than that of the dual-tropic (X4-R5) TCLA strain HIV-1_{MNP}. Among the neutralization-sensitive viruses, the V3 sequence motifs of HIV-1_{BZ167} and

HIV-1_{SF2} shown in Fig. 5 did not correlate with the observed neutralization profiles of HIV-1 Env V3.

(iii) V3 peptide-specific T-cell responses. Table 2 offers a comparison of the virus-specific T-cell response levels determined by IFN- γ ELISPOT analysis in immunized animals with the neutralization data provided in Fig. 2. Of the 15 animals immunized with rBCG Env V3 (180 and 160 SFC/ 10^6 PBMC at 6 weeks postimmunization [p.i.], respectively), only R-09 and R-10 showed very low levels of SFC activities at the time of




FIG. 3. HIV-1-specific neutralization antibody responses in macaques vaccinated with rBCG Env V3. Analysis of in vitro neutralization of SHIV-MN by anti-rBCG-HIV-1 antibodies using M8166 cell-based virus neutralization assays. Serum IgG was purified from preimmune or immune sera of macaques inoculated with rBCG Env V3 at the indicated times. The results are expressed as the means \pm SD of four independent assays.

TABLE 1. 50% neutralization calculated on the basis of neutralization curves^a

Serum sample	Neutralizing activity (μg)						
	BZ167/X4	MNp/X4	SF2/X4	SF33/X4	SF33/R5	VI313/R5	CI2/X4
Group 1	6.5	50	7	>50	>50	>50	10
Group 2	5	50	4	>50	>50	>50	5
Group 3	7	50	6.5	>50	>50	>50	15
Pre immunization sera of groups 1, 2, and 3	>50	>50	>50	>50	>50	>50	>50

^a The neutralization assays with the various viruses were carried out in GHOST cells expressing either CXCR4 (X4) or CCR5 (R5) as indicated in Fig. 4. BZ167, MNp, SF2, SF33, and CI-2 are HIV-1 clade B viruses. VI313 is an HIV-1 clade A virus.

SHIV challenge (120 and 110 SFC/10⁶ PBMC at 24 weeks p.i., respectively) (Table 2). In contrast, <100 SFC/10⁶ PBMC were observed in other immunized animals, and <20 SFC/10⁶ PBMC were observed in controls. Thus, the V3 region antigen in the rBCG Env V3 proved unable to induce significant levels of virus-specific T-cell responses in immunized animals.

Challenge with low-dose SHIV-MN. The first group of eight macaques (R-01 through R-08), consisting of five animals that received rBCG Env V3 and three that received control rBCG α -antigen, were intravenously challenged with low-dose SHIV-MN (20 TCID₅₀) at 24 weeks p.i. The cell-associated virus load was measured in PBMC cocultures, and proviral copy numbers were estimated by DNA PCR using primary PBMC genomic DNA. The level of plasma viremia in each macaque was quantified by competitive reverse transcription-

PCR to assess infection and virus replication for 16 weeks after virus challenge (Table 3).

Control macaques vaccinated with the vector alone (R-06 through R-08) were positive in all three viral-load assays 2 weeks after SHIV-MN challenge and remained positive for a follow-up period of 10 weeks. Because only low levels of viral RNA (<10⁴ RNA copies/ml) were transiently detected 2 weeks postchallenge, all three assays (virus isolation, plasma RNA, and proviral DNA) were used for virus detection. Using these criteria, we observed that all three parameters remained negative after low-dose SHIV-MN challenge in three of five macaques vaccinated with rBCG Env V3 (R-02, R-04, and R-05). However, macaque R-01 was transiently positive in all three assays for virus infection at 4 weeks. Another macaque immunized with rBCG Env V3 (R-03) exhibited a sharp in-




FIG. 4. Neutralization of HIV-1_{BZ167} and HIV-1_{SF2} in GHOST-X4 cells by immune sera from macaques vaccinated with rBCG Env V3. Dilutions of immune sera (closed symbols) and preimmune sera (open symbols) were tested in duplicate, and the percent neutralization was calculated using the mean value. The dose-response curves represent the means of three independent assays.




FIG. 5. Alignment of the amino acid sequences of HIV-1 Env V3 from primary and laboratory isolates. The spaces indicate amino acid deletions; dashes indicate homology. The V3 motif of a neutralization-sensitive HIV-1 strain is enclosed in the shaded rectangle (37).

crease in viral load following challenge, and the levels remained high until the animal was sacrificed. These results demonstrate that vaccination with rBCG Env V3 can induce protective immunity in rhesus macaques against a low-dose challenge with SHIV-MN.

Challenge with high-dose SHIV-MN. The second group of eight macaques (R-09 through R-16) was similarly challenged with a higher dose (200 TCID₅₀) of SHIV-MN by intravenous inoculation at 24 weeks p.i. (Fig. 6). Measurements of the viral loads in PBMC and plasma indicated that all the macaques were infected by the high-dose SHIV-MN challenge. However, the level of viremia during the acute phase of viral infection

was reduced by 1 to 2 log units in macaques immunized with rBCG Env V3 compared with controls (from 10⁶ to 10⁷, to <10⁵ to 10⁴ RNA copies/ml) (Fig. 6A). The control macaques developed a transient decrease in CD4⁺-T-cell counts that rebounded to normal levels ~3 weeks postchallenge (Fig. 6B). In contrast, macaques vaccinated with rBCG Env V3 had little or no change in CD4⁺-T-cell numbers.

Despite the low levels of V3 peptide-specific IFN-γ ELISPOT activities noted for animals R-09 and R-10 above (Table 2), these animals exhibited a plasma viral load and a rate of CD4⁺-cell loss after SHIV challenge that was comparable to those seen in the immunized animals designated R-11, -12, and -13. Thus, immunization with rBCG Env V3 generated even low levels of T-cell responses in only 2 animals out of 5 in this group and out of a total of 15 immunized animals. No evidence of higher virus-specific IFN-γ ELISPOT activity was demonstrated in samples obtained 0, 4, or 6 and 24 weeks after vaccination (Table 2), suggesting that few significant cellular anti-SHIV responses were generated and that those few did not affect virus control in this macaque population.

Challenge with pathogenic SHIV-89.6PD. The third group of macaques (R-17 through R-24) was challenged with pathogenic SHIV-89.6PD (20 TCID₅₀) 24 weeks postinoculation. The effects of vaccination with rBCG Env V3 on immune induction against the pathogenic virus were followed for 32 weeks, and the macaques were then autopsied. As shown in

TABLE 2. SHIV-MN-specific serum IgG neutralization titers and Env V3-specific ELISPOT responses^a

Monkey no.	Immunogen	IC ₅₀ of neutralization serum IgG (μg/ml) ^b			V3-specific IFN-γ SFCs/10 ⁶ cells ^c		
		0 week	4 or 6 weeks ^d	24 weeks ^e	0 week	4 or 6 weeks	24 weeks
R-01	rBCG Env V3	>50	0.5	0.6	<20	30	20
R-02	rBCG Env V3	>50	0.3	0.4	<20	40	40
R-03	rBCG Env V3	>50	0.5	0.6	<20	40	30
R-04	rBCG-Env V3	>50	0.2	0.3	<20	20	40
R-05	rBCG-Env V3	>50	0.08	0.3	<20	30	80
R-06	rBCG-α	>50	>50	>50	<20	<20	<20
R-07	rBCG-α	>50	>50	>50	<20	<20	<20
R-08	rBCG-α	>50	>50	>50	<20	<20	<20
R-09	rBCG-Env V3	>50	0.04	0.3	<20	180	120
R-10	rBCG-Env V3	>50	0.1	0.2	<20	160	110
R-11	rBCG-Env V3	>50	0.05	0.2	<20	20	30
R-12	rBCG-Env V3	>50	0.03	0.4	<20	60	20
R-13	rBCG-Env V3	>50	0.02	0.4	<20	30	30
R-14	rBCG-α	>50	>50	>50	<20	<20	<20
R-15	rBCG-α	>50	>50	>50	<20	<20	<20
R-16	rBCG-α	>50	>50	>50	<20	<20	<20
R-17	rBCG-Env V3	>50	0.2	0.6	<20	40	90
R-18	rBCG-Env V3	>50	0.3	0.3	<20	50	60
R-19	rBCG-Env V3	>50	0.3	0.4	<20	40	30
R-20	rBCG-Env V3	>50	0.5	0.7	<20	20	50
R-21	rBCG-Env V3	>50	0.4	0.5	<20	20	40
R-22	rBCG-α	>50	>50	>50	<20	<20	<20
R-23	rBCG-α	>50	>50	>50	<20	<20	<20
R-24	rBCG-α	>50	>50	>50	<20	<20	<20

^a Animals were inoculated with either rBCG Env V3 or the vector control. Blood samples were obtained at 0, 4, or 6 and 24 weeks p.i., and antibody inhibitory concentration and the V3-specific IFN-γ ELISPOT activity were compared.

^b The IC₅₀ was derived from the data in Fig. 2 based on neutralization dose-response curves similarly obtained from Fig. 3.

^c Freshly isolated PBMC were assessed for their ability to produce IFN-γ in response to HIV-1_{MN} Env V3 peptide.

^d Mean IC₅₀s: R-01 to R-05, 0.32; R-09 to R-13, 0.05; R-17 to R-21, 0.35.

^e Mean IC₅₀s: R-01 to R-05, 0.44; R-09 to R-13, 0.30; R-17 to R-21, 0.50.

TABLE 3. Comparison of low-dose SHIV-MN infections in macaques vaccinated with either rBCG Env V3 or rBCG- α (control)

Monkey	Immunogen (10 mg)	Efficacy analysis	Results ^a								
			0 ^b	2	4	6	8	10	12	16	
R-01	rBCG Env V3	Virus isolation	<1	<1	2	<1	<1	<1	<1	<1	<1
		Provirus by PCR	<500	<500	>500	<500	<500	<500	<500	<500	<500
		Plasma viral load	<500	<500	20,000	<500	<500	<500	<500	<500	<500
R-02	rBCG Env V3	Virus isolation	<1	<1	<1	<1	<1	<1	<1	<1	<1
		Provirus by PCR	<500	<500	<500	<500	<500	<500	<500	<500	<500
		Plasma viral load	<500	<500	<500	<500	<500	<500	<500	<500	<500
R-03	rBCG Env V3	Virus isolation	<1	32	<1	<1	2	<1	ND	ND	
		Provirus by PCR	<500	>500	<500	<500	>500	<500	ND	ND	
		Plasma viral load	<500	310,000	<500	<500	20,000	<500	ND	<500	
R-04	rBCG Env V3	Virus isolation	<1	<1	<1	<1	<1	<1	ND	ND	
		Provirus by PCR	<500	<500	<500	<500	<500	<500	ND	ND	
		Plasma viral load	<500	<500	<500	<500	<500	<500	<500	<500	
R-05	rBCG Env V3	Virus isolation	<1	<1	<1	<1	<1	<1	<1	ND	
		Provirus by PCR	<500	<500	<500	<500	<500	<500	<500	ND	
		Plasma viral load	<500	<500	<500	<500	<500	<500	<500	<500	
R-06	rBCG- α	Virus isolation	<1	32	16	<1	2	2	<1	1<	
		Provirus by PCR	<500	>500	>500	>500	>500	>500	>500	500	
		Plasma viral load	<500	300,000	50,000	20,000	20,000	20,000	20,000	20,000	
R-07	rBCG- α	Virus isolation	<1	2	32	<1	<1	<1	<1	ND	
		Provirus by PCR	<500	>500	>500	>500	>500	<500	<500	ND	
		Plasma viral load	<500	27,000	310,000	350,000	25,000	<500	<500	<500	
R-08	rBCG- α	Virus isolation	<1	32	16	<1	2	2	ND	ND	
		Provirus by PCR	<500	>500	>500	>500	>500	>500	ND	ND	
		Plasma viral load	<500	300,000	50,000	<500	20,000	20,000	ND	<500	

^a Viral loads were determined by either limiting dilution of PBMC or competitive PCR for HIV-1 Env V3 genes, and the results are expressed as the number of infected cells per million PBMC and virus copies per milliliter of blood. Nested PCR for HIV-MN Env V3 was used in all macaques to detect the provirus genome. Naïve macaques were injected intravenously with 20 TCID₅₀ of SHIV-MN and used as controls for SHIV infection. The results are expressed as the mean of three different assays; <1, <500, and <500 were the detection limits of virus isolation, proviral copy number, and plasma viral load, respectively. ND, not determined.

^b Weeks after challenge.

Fig. 7, high levels of plasma viremia were detected in the control macaques, with a viral set point of $\sim 10^6$ RNA copies/ml, accompanied by an abrupt decline in CD4⁺-T-cell counts. Prior vaccination with rBCG Env V3 appeared to have no positive effect on the viral load and CD4⁺-T-cell counts compared with the control animals.

Association of in vitro neutralization antibody responses following rBCG Env V3 immunization with control of viremia after SHIV challenge. Of the macaques challenged with low doses of homologous SHIV-MN (group 1), the three virus-controlled macaques R-02, -04, and -05 (Table 1) had higher IC₅₀s of SHIV-MN-specific neutralizing antibodies as measured in M8166 cells at 24 weeks p.i. or on the day of challenge, with serum IgG concentrations of 0.4, 0.3, and 0.3 μ g/ml, respectively (Table 2). The IC₅₀s of the uncontrolled macaques R-01 and -03 (Table 1) were both 0.6 μ g/ml (Table 2).

When the challenge dose was increased 10-fold (Fig. 1), all five animals in group 2 had high neutralizing antibody titers with a mean IC₅₀ of 0.30 μ g/ml on the day of challenge (Table 2). These animals in group 2 showed partial protection against the same homologous virus challenge (Fig. 6). In contrast, no animals similarly immunized with rBCG elicited any in vivo protection against a low-dose, heterologous viral challenge with SHIV-89.6PD (Table 2 and Fig. 7).


In summary, the rBCG Env V3-elicited NAb response afforded some degree of protection against a homologous viral challenge. However, infection by the heterologous virus SHIV-89.6PD was not controlled by heterologous virus SHIV-MN- or HIV-1_{MN}-specific NAb generated by the recombinant HIV-1_{MN} Env V3-expressed BCG immunization.

DISCUSSION

First, our study demonstrates the potential of anti-Env V3 NAb induced by immunization of rhesus macaques with rBCG Env V3 to afford protection against homologous challenge with SHIV-MN but not against the heterologous SHIV-89.6PD. With the low-dose homologous SHIV-MN challenge (20 TCID₅₀), sterile protection was achieved in three of five immunized animals. These findings correlate well with our in vitro neutralization data for these animals. Protected animals showed higher levels of potent neutralization antibodies than did unprotected animals. Macaques serving as vector and naïve controls experienced high levels of replication of the SHIV-MN challenge virus. With a high-dose challenge, rBCG Env V3 vaccination was effective at reducing viremia during acute infection by ~ 100 -fold. The vaccine consisted of an rBCG vector that expresses a chimeric HIV-1 Env V3 region peptide and the α -antigen of *M. bovis*. The kinetics and magnitude of the HIV-1 Env V3-specific antibody responses elicited in macaques were comparable to those observed in our previous studies using guinea pigs vaccinated with rBCG Env V3 (9, 16).

Secondly, the levels of neutralizing antibodies generated after injection with a recombinant BCG vector-based vaccine expressing a chimeric protein of HIV-1 Env V3 peptide and α -antigen protein were maintained for at least 24 weeks p.i. with no diminishment in titer. A plausible explanation for the longevity of the neutralizing antibody titers after rBCG immunization is that the carrier protein, α -antigen (also known as MPT59 or antigen 85B), is derived from mycobacteria and has

A



B




FIG. 6. Comparison of infection kinetics following high-dose (200 TCID₅₀) inoculation of SHIV-MN in macaques vaccinated with either rBCG Env V3 or rBCG vector control. (A) Viral RNA copy number per milliliter of serum. (B) CD4⁺-T-cell count as a percentage of total lymphocytes. The results in individual animals are expressed.

the ability to elicit potent Th1-type immune responses (24, 43). Our result is consistent with those of other groups, which have shown that BCG immunity is maintained for at least a few years and that the BCG bacillus is effective at increasing NAb responses (40). These characteristics might help to explain the long-lasting enhanced levels of NAb elicited by vaccination with rBCG Env V3.

The concentration of purified macaque IgG in serum was determined to be ~10 mg/ml. By this estimation, 0.5 mg corresponds to a serum dilution of 1:1 in virus neutralization assays. The IC₅₀ and IC₉₀ values for neutralization of SHIV-MN were 10³ to 10⁴ and 166, respectively (similar values were obtained for neutralization of HIV-1_{MN}). These neutralization titers suggest that antibody responses generated de novo may contribute to a degree of protection against SHIV-MN. The observed relationship of the NAb titer and viral protection is consistent with results obtained by repeated immunization with SHIV-89.6 C4-V3 peptides in guinea pigs and rhesus macaques (6, 27). In this case, NAb titers to homologous SHIV-89.6 were ~10³ greater than those against heterologous HIV-1_{MN}, while responses to HIV-1 R5 viruses were weak or absent. This suggests that the protection mediated by a C4-V3 peptide vaccine against SHIV-89.6 may be type (or strain) specific. Thus, we assume that the NAb generated by

SHIV-89.6 C4-V3 peptide immunization (6) would not mediate protection against a heterologous SHIV-MN challenge.

The present study suggests that the vaccine-elicited antibodies directed against the HIV-1 Env V3 peptide can in some cases confer a degree of neutralization against primary isolates of HIV-1 (26). Following vaccination of rhesus macaques with rBCG Env V3, both binding and NAb responses against this novel construct were clearly evident. At the time of SHIV challenge, immune sera from the vaccinated macaques efficiently neutralized a homologous, type-specific TCLA HIV-1 strain (HIV-1_{MN}) and a related SHIV strain (SHIV-MN) with IC₉₀ values of <5 μg/ml. Controls, including preimmune sera and sera from macaques vaccinated with rBCG vector alone, had no neutralizing activity in assays using GHOST cells expressing either CCR5 or CXCR4 or in M8166 cells. Immune sera from macaques vaccinated with rBCG Env V3 were able to neutralize several primary HIV-1 X4 isolates (HIV-1_{BZ167}, HIV-1_{SF2}, and HIV-1_{CT2}); however, neutralization of an X4-R5 dual-tropic strain (HIV-1_{MNp}) was weak. No neutralization of HIV-1 R5 isolates and primary HIV-1 isolates from different clades was observed. These findings were confirmed in an independent international neutralization trial (conducted by Simon Beddows and Jonathan Weber, Imperial College School of Medicine, Medical Research Council, London, En-




FIG. 7. Comparison of infection kinetics following challenge with pathogenic SHIV-89.6PD in macaques vaccinated with either rBCG Env V3 or rBCG vector control. (A) Plasma viral-RNA copy numbers per milliliter. (B) CD4⁺-T-cell count as a percentage of total lymphocytes. The results in individual animals are expressed.

gland, and Pia Scott and Eva-Maria Fenyo at Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm, Sweden). Preliminary results from this study have had been summarized and reported (11). Despite similarities in the V3 sequence motif, neutralization of the TCLA strain HIV-1_{MN} was found to be 10- to 50-fold more sensitive than neutralization of primary HIV-1 isolates, such as HIV-1_{CL2}, HIV-1_{MNP}, or HIV-1_{JR-CSF} (11). A reasonable explanation for the relative insensitivity of primary HIV-1 isolates—particularly primary HIV-1 R5 isolates—to neutralization is the presence of cryptic or occluded sites within the virus-associated V3 region (13, 53).

In the Japanese consensus HIV-1 Env V3 expressed in the rBCG construct, the core V3 motif of the neutralization epitope is IHIGPGRAF (39). Although the consensus sequence of the V3 loop differs from the MN-V3 sequence in five amino acid positions, the neutralization epitope of the tip V3 region in the Japanese consensus is identical to that of MN-V3. Some substitutions of amino acids at certain positions within this motif (for example, H to R and A to T in the core motif in BZ167) are tolerated, suggesting that NAbS generated by immunization with rBCG Env V3 are not strictly type specific. Immune sera from macaques vaccinated with rBCG Env V3 were able to neutralize primary HIV-1 X4 and some HIV-1 X4-R5 dual-tropic isolates, suggesting that the antigenic struc-

ture of the chimeric V3 peptide mimics to some extent that of the virus-associated V3 region. Indeed, the chimeric V3- α -antigen protein is estimated to be 38 kDa and contains four cysteine residues, suggesting the possible formation of a new loop structure in the V3 portion of the protein. With regard to the heterologous SHIV-89.6PD challenge in macaques vaccinated with rBCG Env V3, NAbS specific for SHIV-89.6PD were not generated efficiently (IC_{50} , >50 μ g of immune serum IgG/ml) and did not provide any protection against the SHIV-89.6PD challenge. The V3 neutralization site of SHIV-89.6PD may differ in sequence or structure or both from that of SHIV-MN or other viral strains, including some of the HIV-1 isolates, making it unrecognizable to antibodies. Such a difference could account for the poor cross-neutralization activity against SHIV-89.6PD.

Thus, our data from the SHIV-macaque models show that the in vitro neutralization titers generated in rBCG-immunized animals correlate with protection. Although a present goal of HIV-1 vaccine development is to reduce the viral set point by eliciting high levels of virus-specific cellular immune responses, induction of cross-reactive NAbS may also contribute to control virus replication in the course of HIV-1 infection and may therefore be useful in the context of a preventive vaccine. Furthermore, although the choice of HIV Env V3 and the

autologous challenge virus SHIV-MN are unlikely to provide information that predicts efficacy in humans, the results presented here demonstrate that recombinant BCG vectors have the potential to deliver a more appropriate immunogen for desirable immune elicitation.

ACKNOWLEDGMENTS

We thank L. Yichen, Harvard AIDS Institute, Harvard University, and A. Schultz, NIAID, National Institutes of Health, for providing the SHIV strains and for their helpful discussions. We also thank J. Esparza and S. Osmanov, UNAIDS, Geneva, Switzerland; S. Beddows and J. Weber, Medical Research Council, London, United Kingdom; and Eva-Maria Fenyo, Microbiology and Tumorbiology Center Karolinska, Stockholm, Sweden, for their helpful discussions.

This work was supported by a grant-in-aid from the Ministry of Health and Welfare, Japan, and the Japan Health Sciences Foundation (grants 341-5 and 321-2).

REFERENCES

- Aldovini, A., and R. A. Young. 1991. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. *Nature* 351:479-482.
- Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, M. A. Candido, N. L. Kozry, P. L. Earl, J. M. Smith, H. L. Ma, B. D. Grimm, M. L. Hulse, J. Miller, H. M. McClure, J. M. McNicholl, B. Moss, and H. L. Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. *Science* 292:69-74.
- Baba, T. W., V. Liska, A. H. Khlmani, N. B. Ray, P. J. Dalley, D. Pennick, R. Bronson, M. F. Greene, H. M. McClure, L. N. Martin, and R. M. Ruprecht. 1999. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. *Nat. Med.* 5:194-203.
- Baba, T. W., Y. S. Jeong, D. Pennick, R. Bronson, M. F. Greene, and R. M. Ruprecht. 1995. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. *Science* 267:1820-1825.
- Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W. Wagner, M. Biliska, A. Craiu, X. X. Zheng, G. R. Krivulka, K. Beaudry, M. A. Lifton, C. E. Nickerson, W. L. Trigona, K. Punt, D. C. Freed, L. Guan, S. Dubey, D. Casimiro, A. Simon, M. E. Davies, M. Chastain, T. B. Strom, R. S. Gelman, D. C. Montefiori, M. G. Lewis, E. A. Emini, J. W. Shiver, and N. L. Letvin. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. *Science* 290:486-492.
- Barouch, D. H., S. Santra, M. J. Kuroda, J. E. Schmitz, R. Plishka, A. Buckler-White, A. E. Gaitan, R. Zin, J. H. Nam, L. S. Wyatt, M. A. Lifton, C. E. Nickerson, B. Moss, D. C. Montefiori, V. M. Hirsch, and N. L. Letvin. 2001. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. *J. Virol.* 75:5151-5158.
- Bloom, B. R. 1989. New approaches to vaccine development. *Rev. Infect. Dis.* 11(Suppl. 2):S460-S466.
- Cecilia, D., V. N. KewalRamani, J. O'Leary, B. Volsky, P. Nyambi, S. Burda, S. Xu, D. R. Littman, and S. Zolla-Pazner. 1998. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. *J. Virol.* 72:6988-6996.
- Chujoh, Y., K. Matsuo, H. Yoshizaki, T. Nakasatomi, K. Someya, Y. Okamoto, S. Naganawa, S. Haga, H. Yoshikura, A. Yamazaki, S. Yamazaki, and M. Honda. 2002. Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E' and B' strains by recombinant *Mycobacterium bovis* BCG-based candidate vaccine. *Vaccine* 20:797-804.
- Earl, P. L., L. S. Wyatt, D. C. Montefiori, M. Biliska, R. Woodward, P. D. Markham, J. D. Malley, T. U. Vogel, T. M. Allen, D. I. Watkins, N. Miller, and B. Moss. 2002. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. *Virology* 294:270-281.
- Falk, L. A., K. L. Goldenthal, J. Esparza, M. T. Aguado, S. Osmanov, W. R. Ballou, S. Beddows, N. Bhamarapavati, G. Biberfeld, G. Ferrari, D. Hofst, M. Honda, A. Jackson, Y. Lu, G. Marchal, J. McKinney, and S. Yamazaki. 2000. Recombinant bacillus Calmette-Guerin as a potential vector for preventive HIV type 1 vaccines. *AIDS Res. Hum. Retrovir.* 16:91-98.
- Feinberg, M. B., and J. P. Moore. 2002. AIDS vaccine models: challenging challenge viruses. *Nat. Med.* 8:207-210.
- Ghiara, J. B., E. A. Stura, R. L. Stanfield, A. T. Profy, and I. A. Wilson. 1994. Crystal structure of the principal neutralization site of HIV-1. *Science* 264:82-85.
- Haynes, B. F., S. B. Putman, and J. B. Weinberg. 1996. Update on the issues of HIV vaccine development. *Ann. Med.* 28:39-41.
- Hiroi, T., H. Goto, K. Someya, M. Yanagita, M. Honda, N. Yamanaka, and H. Kiyono. 2001. HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions. *J. Immunol.* 167:5862-5867.
- Honda, M., K. Matsuo, T. Nakasone, Y. Okamoto, H. Yoshizaki, K. Kitamura, W. Sugiura, K. Watanabe, Y. Fukushima, S. Haga, Y. Katsura, H. Tasaka, K. Komuro, T. Tamada, T. Asano, A. Yamazaki, and S. Yamazaki. 1995. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant *Mycobacterium bovis* bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. *Proc. Natl. Acad. Sci. USA* 92:10693-10697.
- Jin, X., S. Yamamoto, M. Cheng, K. Yasukawa, H. Suzuki, T. Saito, Y. Osugi, T. Tokunaga, and T. Kishimoto. 1992. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. *J. Immunol.* 148:2175-2180.
- Izumi, Y., Y. Ami, T. Nakasone, K. Matsuo, K. Someya, T. Sata, N. Yamamoto, and M. Honda. 2003. Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus Gag controls highly pathogenic simian-human immunodeficiency virus in monkeys. *J. Virol.* 77:13248-13256.
- Jin, X., D. E. Bauer, S. E. Tuttleton, S. Lewin, A. Gettie, J. Blanchard, C. E. Irwin, J. T. Safritz, J. Mittler, L. Weinberger, L. G. Kostrikis, L. Zhang, A. S. Perelson, and D. D. Ho. 1999. Dramatic rise in plasma viremia after CD8⁺ T cell depletion in simian immunodeficiency virus-infected macaques. *J. Exp. Med.* 189:991-998.
- Karlsson, G. B., M. Halloran, J. Li, I. W. Park, R. Gomila, K. A. Reimann, M. K. Axthelm, S. A. Iff, N. L. Letvin, and J. Sodroski. 1997. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4⁺ lymphocyte depletion in rhesus monkeys. *J. Virol.* 71:4218-4225.
- Kawahara, M., A. Hashimoto, I. Toida, and M. Honda. 2002. Oral recombinant *Mycobacterium bovis* bacillus Calmette-Guerin expressing HIV-1 antigens as a freeze-dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. *Clin. Immunol.* 105:326-331.
- Kawahara, M., K. Matsuo, T. Nakasone, T. Hiroi, H. Kiyono, S. Matsumoto, T. Yamada, N. Yamamoto, and M. Honda. 2002. Combined intrarectal/intradermal inoculation of recombinant *Mycobacterium bovis* bacillus Calmette-Guerin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen. *Vaccine* 21:158-166.
- Kitsutani, P. T., S. Naganawa, T. Shiino, M. Matsuda, M. Honda, K. Yamada, M. Taki, and W. Sugiura. 1998. HIV type 1 subtypes of nonhemophilic patients in Japan. *AIDS Res. Hum. Retrovir.* 14:1099-1103.
- Kuromatsu, I., K. Matsuo, S. Takamura, G. Kim, Y. Takebe, J. Kawamura, and Y. Yasutomi. 2001. Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an alpha antigen from mycobacteria. *Cancer Gene Ther.* 8:483-490.
- Letvin, N. L., D. H. Barouch, and D. C. Montefiori. 2002. Prospects for vaccine protection against HIV-1 infection and AIDS. *Annu. Rev. Immunol.* 20:73-99.
- Letvin, N. L., S. Robinson, D. Rohne, M. K. Axthelm, J. W. Fantom, M. Biliska, T. J. Palker, H. X. Liao, B. F. Haynes, and D. C. Montefiori. 2001. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. *J. Virol.* 75:4165-4175.
- Liao, H. X., B. Etamad-Moghadam, D. C. Montefiori, Y. Sun, J. Sodroski, R. M. Scearce, R. W. Doms, J. R. Thomasch, S. Robinson, N. L. Letvin, and B. F. Haynes. 2000. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains. *J. Virol.* 74:254-263.
- Lifson, J. D., and M. A. Martin. 2002. One step forwards, one step back. *Nature* 415:272-273.
- Lu, Y., M. S. Salvato, C. D. Pauza, J. Li, J. Sodroski, K. Manson, M. Wyand, N. Letvin, S. Jenkins, N. Touzjian, C. Chutkowski, N. Kushner, M. LeFaille, L. G. Payne, and B. Roberts. 1996. Utility of SHIV for testing HIV-1 vaccine candidates in macaques. *J. Acquir. Immune Defic. Syndr. Hum. Retrovir.* 12:99-106.
- Matsumoto, S., M. Tamaki, H. Yukitake, T. Matsuo, M. Naito, H. Teraoka, and T. Yamada. 1996. A stable *Escherichia coli*-mycobacteria shuttle vector 'pSO246' in *Mycobacterium bovis* BCG. *FEMS Microbiol. Lett.* 135:237-243.
- McCune, J. M. 2001. The dynamics of CD4⁺ T-cell depletion in HIV disease. *Nature* 410:974-979.
- Mori, K., Y. Yasutomi, S. Ohgimoto, T. Nakasone, S. Takamura, T. Shioda, and Y. Nagai. 2001. Quintuple deglycosylation mutant of simian immunodeficiency virus STVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain. *J. Virol.* 75:4023-4028.
- Mothe, B. R., H. Horton, D. K. Carter, T. M. Allen, M. E. Liebl, P. Skinner, T. U. Vogel, S. Fuenger, K. Vielhuber, W. Rehauer, N. Wilson, G. Franchini, J. D. Altman, A. Haase, L. J. Picker, D. B. Allison, and D. I. Watkins. 2002. Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. *J. Virol.* 76:875-884.